ISSN 0959-8049
Publisher: Elsevier
< previous issue | all issues | next issue >
Rectal cancer treatment in the next century pp. 1-1(1) Author: Pahlman L.
Genetic developments and nursing practice: the future is closer than you think! pp. 5-5(1) Author: Batchelor D.
Information technology and cancer nursing: how to combine technology and touch pp. 6-6(1) Author: Sermeus W.
Developing European standards of nursing care pp. 7-7(1) Authors: Miller M.; Kearney N.
Post-graduate cancer nursing education. From inservice to certification pp. 7-7(1) Authors: Smadar N.; Yaffe A.
Nursing problems in surgical oncology, can we predict them? pp. 7-7(1) Authors: de Kruif J.T.C.M.; van den Berg H.B.
A new treatment for the head and neck cancer patient. Radplat: a nursing challenge! pp. 7-7(1) Author: Visser J.C.
Integrating in- and out-patient nursing services for breast cancer patients undergoing mastectomy and breast conserving surgery pp. 8-8(1) Author: van Wijngaarden M.G.
Nurse's counselling role in cancer pp. 8-8(1) Author: Ferrario R.
The use of a telephone triage (TT) for an out of hours service in transmural palliative care pp. 8-8(1) Authors: Elfrink E.J.; Elswijk P.; van der Rijt C.C.D.
The crisis of sudden death: an unmet need in cancer care? pp. 8-8(1) Author: Porter H.
Representative information on side-effects of chemotherapy pp. 8-9(2) Author: Heijer A.D.-d.
The 'Chemo-Quiz', a creative way to learn pp. 9-9(1) Authors: de Ruijter W.; Eeltink C.M.
''Plastic surgery over-then what?'' The development of a network to help patients cope with altered body image and self concept following surgery pp. 9-9(1) Authors: Burton A.; Cunningham T.; Plaiter T.
Trained professionals as a resourse in canser care and treatment. A co-operative model for professional development and continuity in the public health system pp. 9-9(1) Author: Kolsvik E.
Community palliative care needs assessment pp. 9-9(1) Author: Garland E.
Backbone for research nurses within the new drug development team: improving efficiency and communication pp. 9-10(2) Author: van Wijk A.W.
Regular counselling by an oncology nurse increases coping with side effects during outpatients radiotherapy of gynecological malignancies pp. 10-10(1) Authors: Varre P.; Jacobsen A.M.; Flovik A.M.; Skovlund E.; Fossa S.D.
How important is the role of the research nurse in the care of patients entered into cancer clinical trials? pp. 10-10(1) Authors: Varcoe S.M.; Elliott M.E.
Group protocol for the administration of adjuvant chemotherapy using, cyclophosphamide, methorexate, and 5fluorouracil (C.M.F.) to patients with breast cancer, by nurses within an out-patient setting pp. 10-10(1) Author: Ryan D.
An exploratory study examining patients' perceptions of rehabilitation following bowel cancer pp. 10-10(1) Author: Howard-Jones G.
Continuous nurse education: improving cancer care through education for nurses pp. 10-11(2) Author: Laze I.
Using the audit cyccle to change practice: developing an holistic approach to delivery of chemotherapy pp. 11-11(1) Author: Richardson H.
Organisation of chemotherapy services and patient care in adepartment of medical oncology of a comprehensive cancer centre: role of a nurse in transitional period of the society pp. 11-11(1) Author: Kocanova J.
Hospice at Home: a 2 year pilot project providing specialist palliative care at home pp. 11-11(1) Authors: Graham J.; McGill M.; Munroe S.
Preceptorship package: finding your way in a new specialty pp. 11-11(1) Authors: Prince A.; Shrewbridge A.; Cathmoir D.
Cancer patients seeking information from sources outside the health care system pp. 11-12(2) Author: Carlsson M.
A strategy for advancing practice; paediatric oncology nursing pp. 12-12(1) Author: Gibson F.
The role of the specialist oncology nurse practitioner in delivering accelerated, dose-intensive chemotherapy with autologous, progenitor cell-enriched whole blood re-infusion pp. 12-12(1) Author: Diffley J.
Altered body image following adolescent bone cancer pp. 12-12(1) Author: Nendick M.E.
Everyday coping of adolesecents with cancer pp. 12-12(1) Authors: Seppanen P.; Jamsa T.; Mikkonen R.; Nousiainen E.-M.; Rytilahti M.; Vattovaara R.; Kyngas H.
Anaphylaxis within the chemotherapy setting explained pp. 12-13(2) Author: Nendick M.E.
Every nurse a leader! pp. 13-13(1) Author: Dellepoort W.T.A.
Interactive session. Ambulatory infusional therapy pp. 14-14(1) Authors: Oakley C.; Wright E.
A nurse's guide to the Internet pp. 14-14(1) Authors: Krcmar H.; Krcmar C.
Ambulatory infusional therapy - Workshop pp. 14-14(1) Author: Jocham H.
Stem cell transplantation, a treatment for patients with solid tumours and haematological malignancies. Implications for oncology nursing practice pp. 14-14(1) Author: Larsen J.
Research in oncology nursing: the way forward pp. 15-15(1) Author: Di Giulio P.
The research practice interface pp. 15-15(1) Author: Rafferty A.M.
Bridging over the gap: foundation of a nursing research committee in order to achieve research based care of haematology and oncology patients pp. 16-16(1) Authors: Schoenmakers J.F.; van Nierop G.; de Graaf J.P.; Pison E.C.
To be on a side track... a qualitative study of BMT patients with focus on the transition from long time hospitalisation and physical isolation to being back home again pp. 16-16(1) Author: Esbensen B.A.
Selecting hermeneutic phenomenology as a research methodology in cancer nursing: a clinical perspective pp. 16-16(1) Author: Foy S.
The validity of faecal occult blood (FOB) testing in population screening for colorectal cancer (CRC) pp. 16-16(1) Authors: Craven O.; Meah S.
Central venous access ports-pros and cons: a nursing perspective pp. 17-17(1) Authors: Myburgh L.; van Vuuren M.J.; Raats J.I.
Pain of cancer patients in radiation therapy pp. 17-17(1) Authors: De la Fuente y Briones F.; Buchborn K.; Bormeth S.; Zander-Heinz A.C.; Budischewski K.; Bottcher H.D.
Cancer care: priorities for nurses - Evaluation of a workshop on infections pp. 17-17(1) Authors: Thain C.W.; Ion E.; Podmore L.; Woods S.
A comparative study of fatigue in patients who have completed a course of chemotherapy and health individuals pp. 17-17(1) Authors: Nicholas E.C.; Richardson A.
Assessment of alternative and complimentary medicines and devices in cancer patients attending a multi-disciplinary cancer centre pp. 17-18(2) Authors: Harris L.; Naidoo S.; Vorobiof D.A.; Chasen M.R.
Continous infusion therapy: for how long can a Huber needle be left in situ without being changed? Use of a non adherent silicone dressing (Mepitel) under the Huber needle in order to prevent sores in obese patients and in patients with a deep port-a-cath pp. 18-18(1) Authors: Milani A.; Lunghi L.; Vernizzi S.; Passoni C.; Sociale O.; Macciola F.; Ravenna S.; Remoli S.; Grimaldi C.; Sciancalepore N.
The research nurses role in the study of patients recieving once weekly radiotherapy for locally advanced or recurrent rectal cancer pp. 18-18(1) Authors: Brooker S.; Tait D.; Glees J.P.; Cook A.; Norman A.
Does exist an oncological patient profile who use alternative therapies? pp. 18-18(1) Authors: Fernandez P.; Martinez I.; Iglesias I.; Eito C.; Fernandez I.
Empowering the cancer patient with chronic pain pp. 18-18(1) Authors: de Ruijter W.; van Dam F.S.A.M.; Jongkind J.F.; Witkamp F.E.; de Wit R.; Passchier J.; Vecht C.J.
Relating information needs to the cancer experience: the perspectives of people with cancer pp. 18-19(2) Author: van der Molen B.
Two out of three cancer patients receiving chemotherapy experience fatique pp. 19-19(1) Authors: Tanghe A.; Evers G.; Spinnoy M.
Fatigue in breastcancer patients undergoing adjuvant chemotherapy pp. 19-19(1) Authors: de Jong N.; Courtens A.M.; Schouten H.
Reflections on the challenges of conducting international, multi-institutional research - Assessment of cancer-related fatique pp. 19-19(1) Authors: Richardson A.; Ream E.K.; Piper B.F.; Dodd M.J.
Breast cancer screening in older women: a dual site intervention study Northeast/Southeast USA pp. 19-19(1) Authors: Wood R.; Morris S.; Watson M.
Measuring attitudes of oncology health professionals towards elderly people with cancer pp. 20-20(1) Authors: Miller M.; Kearney N.; Smith K.
Information needs of newly diagnosed cancer patients pp. 20-20(1) Author: Ablett-Spence I.
The development of an instrument to assess patients' experiences of side effects of cytotoxic chemotherapy pp. 20-20(1) Authors: Brown V.; Sitzia J.; Richardson A.; Hughes J.; Yeomans J.; Hannon H.; Dikken C.
Prevalence and distress of taste loss after radiotherapy of head and neck pp. 20-20(1) Authors: Evers G.; Huygh I.; Van Den Bogaert W.; Vandevelde G.
Validation of a French version of the Piper Fatigue Scale (PFS) pp. 20-20(1) Authors: Gledhill J.A.; Boisvert C.; Mahe C.; Rodary C.
Design of a longitudinal perspective study of fatigue in patients with cancer pp. 21-21(1) Authors: Robertshaw H.; Richardson A.
Chronic breast/chest wall pain following treatment for breast cancer - A research nurse led study pp. 21-21(1) Author: Moat S.L.
Provision of information concerning gynaecological cancer and sexuality: the patient's perspective pp. 21-21(1) Authors: Gamel C.; Hengeveld M.; Grypdonck M.; Davis B.
Assessing chemotherapy side effects - A critical review of symptom assessment tools pp. 21-21(1) Author: Brown V.
A practical screening form for the nutritional status of hospitalized patients pp. 21-21(1) Authors: de Kruif J.T.C.M.; Vos A.; van Vroonhoven T.J.M.V.
What are the 'needs' of cancer patients and their main carers? pp. 21-22(2) Authors: Thomas C.; Morris S.; McIllmurray M.B.; Soothill K.; Ledwith F.; Francis B.
Antiemetic therapy in colon cancer patients pp. 22-22(1) Authors: Rossi P.; Accardi C.; Augugliaro A.; Bertini F.; Brini G.; Cappelli C.; Nicoletti E.
Prevention of vaginal agglutination by women treated with radiotherapy for cervical cancer pp. 22-22(1) Authors: Hansen A.H.; Fruerlund L.
IntraDose&unknown; (cisplatin/epinephrine) injectable gel for treatment of neoplasms involving the liver: implications for nursing practice pp. 22-22(1) Author: Hupkes M.
The comparative efficacy of counselling & complementary therapy on the minimisation of psychological morbidity in a population of cancer patients pp. 22-22(1) Author: Seddon L.
Hospice at home: baseline study: an evaluation of palliative admissions in north Glasgow pp. 22-23(2) Authors: Graham J.; McGill M.; Deeny M.; Doubal A.; Meldrum T.; Welsh J.
Patient's diary (PD) is the guarantee of quality and safety of clinical trial with CAMPTO pp. 23-23(1) Authors: Zarouk V.; Besova N.
Development and evaluation of information materials for non-English speaking patients pp. 23-23(1) Authors: Speechley V.; Mallett J.
Staff knowledge and attitudes towards cancer pain management on general surgical wards: identifying educational needs pp. 23-23(1) Authors: Wells M.; Dryden H.; Guild P.; Farrer K.; Levack P.; Mackie G.
Accreditation of educational programmes pp. 24-24(1) Author: Vaessen G.
EONS core curriculum pp. 24-24(1) Author: Redmond K.
This house believes that nursing research is irrelevant pp. 25-25(1) Author: Ambaum E.W.C.
Globalizing quality in clinical trials: a nursing perspective on the main changes in the International conference on Harmonization Good Clinical Practice (ICH-GCP) guideline pp. 26-26(1) Author: de Boer M.
The implications of GCP for the organisation of a Clinical Trial (CT) pp. 26-26(1) Author: Colussi A.M.
The ICH-GCP guideline: the patient perspective - Symposium EORTC- Oncology Nursing Study Group pp. 26-26(1) Author: Ambaum E.W.C.
The ICH-GCP guidelines: the nursing perspective pp. 26-26(1) Author: Molin C.M.
Developing evidence based guidelines pp. 27-27(1) Author: Magnusson K.
Reviewing the evidence pp. 27-27(1) Author: Uitterhoeve R.
Reviewing the evidence pp. 27-27(1) Author: Panfil E.-M.
Writing for publication pp. 27-27(1) Author: Robinson L.
Cancer and its consequences on sexuality pp. 29-29(1) Author: Borg T.
Nursing care interventions based on theory and scientific evidence - Implications for justifying radiation oncology nursing practice pp. 29-29(1) Authors: Wengstrom Y.; Forsberg C.
Beating fatigue: evaluation of a programme developed to assist patients receiving chemotherapy cope with fatigue pp. 30-30(1) Authors: Ream E.; Richardson A.
Treatment of platinum-induced anaemia with epoetin alpha (EPO): attitudes of community and hospital based nursing staff pp. 30-30(1) Authors: Deary A.; Dalton L.; Kaminski E.; Thomas R.
Lymphoedema: a retrospective analysis of 196 patients at a large cancer centre, to identify if seroma following axillary dissection for breast cancer is a risk factor for lymphoedema pp. 30-30(1) Author: Compton L.
Treatment of breast cancer related lymphedema with or without manual lymphatic drainage: a randomized study pp. 30-31(2) Authors: Andersen L.; Hojris I.; Andersen J.
Promoting health: challenges within the population with breast cancer related lymphoedema pp. 31-31(1) Author: MacLaren J.
Transdermal fentanyl use in Greek patients with cancer-related pain pp. 31-31(1) Authors: Viha A.; Iconomou G.; Kalofonos H.P.; Vagenakis A.
The concept of hope and its relevance to the cancer setting pp. 31-31(1) Author: Porter H.
Treatment for cervical cancer can have serious implications: a way forward. Sexual dysfunction following radiation both internal and external beams has been a silent unspoken problem for years pp. 31-31(1) Author: Thomas J.
Nonmorphinic analgesic combinations in pain treatment for cancer pp. 31-31(1) Authors: Omet L.; Grigorescu A.C.
A comparison of the neurological toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC) pp. 32-32(1) Authors: Bacon M.; Zee B.; James K.; Stuart G.; Soroka D.; Walsh W.; Bacon E.
Cold-cap - Keeps the head cold and help some women avoiding alopecia through chemotherapy treatment for ovarian cancer pp. 32-32(1) Authors: Tronstad A.K.; Hanshus A.C.; Skogsfjord K.; Storing E.
Scalp cooling for chemotherapy induced alopecia: devising and implementing a unified trust policy pp. 32-32(1) Authors: Brewer D.; Mans L.
Prevention of lymphoedema: a booklet for Greek women with breast cancer pp. 32-32(1) Authors: Pappa D.; Patiraki E.; Chrysanthou V.
Skin and nail disorders: one of the specific non-hematological side effects of docetaxel (taxotere) pp. 32-32(1) Author: De Gucht L.
Clinical experience of ketamine for intractable neuropathic cancer pain pp. 32-33(2) Authors: Mula C.; Penfold R.; Makin W.P.; Smith E.
Multi-professional core care planning: a model to ensure evidence based practice pp. 33-33(1) Author: Porter H.
The information needs of women contemplating breast reconstruction after a diagnosis of breast cancer: a pilot study pp. 33-33(1) Author: Dryden H.
After mastectomy: the nurse's counselling role in breast reconstruction pp. 33-33(1) Author: Ferrario R.
How safe are the patients in your care? The nurses's responsibility for equipment safety-selection, purchasing, maintenance, training and the millennium issues pp. 33-33(1) Author: Dolan S.
Chemotherapy administration by nurses: an audit of practice and educational preparation pp. 34-34(1) Author: Grundy M.
Important remarks by the preparation and administering of cytotoxic drugs pp. 34-34(1) Authors: Claes V.; De Gucht L.; Dhaenekint C.; Ponnet G.; Roeffaers J.; Simons L.; Van Ackerbroeck G.; Van Gaver J.; Van Soom J.; Verpoorten L.; Vranckx P.
The audit results of in-patient chemotherapy management in an acute medical ward pp. 34-34(1) Author: Bagnall S.
Qualifying clinical trail nurses - A danish case stoty pp. 34-34(1) Authors: Brinch A.; Lyngsoe M.; Hostrup P.
A prospective survey of patient satisfaction with the information provided prior to admission to the H.D.U. following major surgery for cancer pp. 34-34(1) Author: Dolan S.
The Blood Transfusion Committee necessary evil - or a major contribution to the patient's care pp. 35-35(1) Author: Dolan S.
Promoting clinical effectiveness in intravenous therapy pp. 35-35(1) Authors: Todd J.; Bravery K.
Autologous peripheral blood stem cell transplantation (PBSCT): ''patient booklet'' pp. 35-35(1) Authors: Van den Bosch S.; Bernasconi D.; De Bartolomei R.; Del Fedele P.; Delle Donne C.; Seminatore M.; Ghielmini M.; Cavalli F.
The use of administrative tools in clinical trials to improve the quality and systemisation of data: the responsibility of the Research Nurse pp. 35-35(1) Authors: Nicolaisen K.; Christiansen B.
An audit of 100 deaths at a regional cancer centre pp. 35-35(1) Authors: Penfold R.; Mula C.; Makin W.
Nursing responsibilities in clinical trials in the Istanbul University Oncology Institute and the implementation of education programmes pp. 36-36(1) Authors: Topuz E.; Aydiner A.; Durna Z.
Qualifying the palliative care at the Roskilde County Hospital - A quality development project pp. 36-36(1) Authors: Esbensen B.A.; Andersen S.; Begelund J.; Johnsen L.; Ottesen S.S.
Venous central line management and complications in patients treated with high-dose chemotherapy and circulating hemopoietic progenitor support (PBPC) pp. 36-36(1) Authors: Gini S.; Guarguaglini E.; Gambini L.; Buonamini I.; Fonti G.; Benanti F.; Bengala C.; Galli L.; Antonuzzo A.; Conte P.F.
The communication of bad news - A Rotterdam perspective pp. 36-36(1) Authors: Koorevaar C.A.; Neeleman W.B.; Rehorst J.; Stojanoski A.
Safe handling of cytotoxic drugs in Slovenia pp. 36-37(2) Authors: Bobnar A.; Velepic M.
Intensity Modulated Radiotherapy (IMRT) of prostate cancer: a greater demand for quality control and daily treatment accuracy pp. 37-37(1) Authors: Bate M.-T.; Demeerleer G.; Van Duyse B.; Vakaet L.; De Neve W.
The need for frequent stimulation and help of the investigators for a good managment in the ''TDM study'' pp. 37-37(1) Authors: Heilmann M.-O.; Trillet-Lenoir V.
Comfortable patients in protocoled trials pp. 37-37(1) Authors: Pedersen I.R.; Akselbo L.
Guideline for patients undergoing chemoembolization pp. 37-37(1) Authors: Salazar J.; Villena M.P.; Vilugron E.; Orlandi F.J.
Use of alginate dressings in the care of chronic wound pp. 37-37(1) Authors: Ursic H.; Salehar A.
Europe against cancer programme - Overview of advancing cancer nursing practice project pp. 38-38(1) Author: Knowles G.
Advancing cancer nursing practice: educating advanced practitioners pp. 38-38(1) Authors: Di Giulio P.; Saiani L.; Brugnolli A.
Using research findings: is it really possible pp. 38-38(1) Authors: Uitterhoeve R.; Ambaum B.
Anxiety levels in family caregivers of cancer patients receiving chemotherapy pp. 38-38(1) Authors: Patiraki E.; Gika M.; Pappa D.; Kiritsi H.; Haralambidou E.; Anagnostopoulos F.
Advancing cancer nursing practice pp. 39-39(1) Author: Corner J.
What constitutes good cancer care in Greece pp. 39-39(1) Author: Efstathiou N.
Therapeutic communications pp. 40-40(1) Author: Lanceley A.
Advances in pain management require new nursing skills pp. 40-40(1) Authors: Vogelaar P.J.W.; Crul B.J.P.
Extravasation bei intravenoser Chemotherapie anhand von Pflegestandards pp. 40-40(1) Author: Wimmer E.
New perspectives on fatigue pp. 40-40(1) Author: Ream E.
Recent developments in palliative care pp. 41-41(1) Author: Kealy K.
Cancer nursing in the new millennium: non-persons or the people in the big house pp. 41-41(1) Author: Kearney N.
Managing patients at home during the aplastic phase of high dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT) pp. 42-42(1) Authors: Holtkamp M.J.; Westermann A.M.; Linthorst G.A.M.; Uyterlinde W.I.; van Leeuwen L.; Willemse E.J.M.; Rodenhuis S.
Evaluation of advanced home care (AHC). The next-of-kin's experiences pp. 42-42(1) Authors: Rollison B.; Carlsson M.
An exploratory study investigating the experiences of patients and nurses with a nurse led peripherally inserted central venous catheter line service pp. 42-42(1) Authors: Oakley C.; Wright E.; Ream E.
The role of the radiotherapy research nurse pp. 42-43(2) Author: Brooker S.
Outpatient parenteral antibiotic therapy (OPAT) in patients with acute leukaemia (AL) and aggressive non-Hodgkin's lymphoma (NHL) pp. 43-43(1) Authors: Johansson E.; Bjorkholm M.; Wredling R.; Engervall P.
Cancer diagnosis: the nurses role in breaking the bad news pp. 43-43(1) Author: Kogelbauer C.
A specialist nurse service for patients with lung cancer: a review of the first year pp. 43-43(1) Author: Johnson M.
A study of contraceptive advice given to chemotherapy patients pp. 43-44(2) Author: Lomax L.
Oncologic nursing evaluation at the Galician comunity pp. 44-44(1) Authors: Davila E.; Diaz F.
Zoledronate, a new 3rd generation bisphosphonate: implications for nursing practice pp. 44-44(1) Authors: Hupkes M.; Givant F.
Family rooms at hospitals - Combining the advantages of the hospice and the facilities of the public hospital pp. 44-44(1) Authors: Linderoth H.R.; Jorgensen C.H.
Management of the outpatient clinic in a breast cancer unit pp. 44-44(1) Authors: Rubio G.; Rossetti B.; Bernasconi P.
A multi-disciplinary 'outcome' round to decrease stress and burnout among Bone Marrow Transplant nurses and to promote disscussion and education; one year on pp. 44-44(1) Author: Stephens M.
Increased willingness for organ donation in cancer patients pp. 44-45(2) Authors: Muller A.; Kretschmar C.; Horn I.; Landenberger M.
The role of the research sister in MRI/oncology pp. 45-45(1) Author: Price N.
A new approach for nurses new to oncology nursing pp. 45-45(1) Authors: Burton A.; Witham G.
Harvesting of peripheral blood stem cells using venesection and subsequent reinfusion of whole blood pp. 45-45(1) Authors: Hodgetts J.; Lomax L.
Handbook for administration of cytostatic agents in order to obtain uniformity in dealing with these pp. 45-45(1) Author: Nielsen E.
Application of educational programme ''To Learn How to Live with Cancer'' in patients with breast cancer for psychosocial adaptation pp. 45-45(1) Authors: Milovic L.; Nikolic S.; Djurdjevic A.
Clinical paths: to increase the quality of nursing in a haematologic center pp. 45-46(2) Authors: Van Asch L.; Gelissen L.; Van Clapdurp C.; Casteels R.; Daniels J.; Zachee P.
An interactive patient information CD ROM on specific side effects in chemo- and radiotherapy pp. 46-46(1) Authors: Vandevelde G.; Peeters J.; Ponnet G.; Vandebotermet J.; Verpoorten L.
Why oncology units should provide a website for their patients pp. 46-46(1) Authors: Dalton L.; Deary A.; Akass K.; Thomas R.
Caring for cancer patients in diverse healthcare environments - Meeting the challenge to educate nurses and healthcare professionals pp. 46-46(1) Authors: Davidge E.M.; Freemantle A.G.
Job sharing senior clinical roles: heaven or hell! pp. 46-47(2) Authors: Cathmoir D.; Mullooly C.; Brewer D.; Miller C.
The development and implementation of a clinical pathway for the diagnosis and staging of lymphoma pp. 47-47(1) Authors: Vanhaecht K.; Sermeus W.; Paridaens R.; Thomas J.
Fatigue in cancer, a new education course for nurses pp. 47-47(1) Authors: Hummel H.; Rietema R.; Vaessen G.
Hospice as a resource centre pilot project. Nursing staff education in the principles of palliative care in private nursing homes pp. 47-47(1) Authors: Fergus L.; Munroe S.; McGill M.; Paterson I.
Recovery & stability, health promotion and rehabilitation for cancer patients pp. 47-47(1) Authors: Gijsen B.C.M.; de la Fonteijne J.M.J.; van den Borne H.W.; Vlaeyen J.W.S.
Surviving changes in health care pp. 48-48(1) Author: Krasuska M.E.
Post-Basic Courses in Cancer Nursing - The impact of continuing education pp. 48-48(1) Author: Bachmann-Mettler I.
Leadership in cancer nursing care pp. 48-48(1) Author: Ferguson A.
Speaker against: this house believes that nurses are able to meet patients' health care needs pp. 49-49(1) Author: Luker K.A.
Speaker in favour: this house believes that nurses are able to meet patients' health care needs pp. 49-49(1) Author: Tishelman C.
Management issues associated with inherited cancer risk pp. 53-53(1) Author: Daly P.A.
Impact of the genetic revolution on nursing practice pp. 53-53(1) Author: Ormiston W.J.
Genetics: a hope for prevention pp. 54-54(1) Author: Murphy A.E.
Does modern oncology need medical genetics? pp. 54-54(1) Author: Murday V.
Psychosocial issues in cancer genetics - Progress and prospects pp. 54-54(1) Author: Cull A.
The experience of hereditary cancer in families - implications for cancer genetics counselling pp. 54-54(1) Author: Ardern-Jones A.
Translating research into practice: the clinician's point of view pp. 55-55(1) Author: Hossfeld D.K.
Evidence based nursing. The key for professional nursing pp. 55-55(1) Author: Beirer A.
Good clinical practice: a label of quality? pp. 57-57(1) Author: Therasse P.
Is our daily nursing practice Good Clinical Practice? pp. 57-57(1) Author: Tanghe A.
Cost of treating colorectal cancers pp. 58-58(1) Author: Kerr D.J.
The impact of telematics and information technology on the management of oncology care pp. 58-58(1) Authors: Sermeus W.; Vanhaecht K.; Kearney N.; Hoy D.; Delesie L.; Hofdijk J.; Kinnunen J.; Mantas J.; Gypen T.; Tansley J.
The costs and benefits of nurse led cancer care pp. 58-58(1) Author: Corner J.
Usefulness of medico-economic studies in cancer care from the perspective of payers and policy makers? pp. 59-59(1) Author: Viens G.
Parenteral infusion from hospital to home treatment: cost-effective? pp. 61-61(1) Authors: Witteveen P.O.; Van Boxtel A.J.H.
Parenteral infusion from hospital to home treatment: a feasible option? pp. 61-61(1) Authors: Van Boxtel A.J.H.; Witteveen P.O.
Cancer treatment - Major questions for the new millennium pp. 65-65(1) Author: McVie J.G.
Paediatric tumours - What have we learnt? General messages for oncologists pp. 65-65(1) Author: Gadner H.
The impact of biology on the practice of radiotherapy pp. 65-65(1) Author: James N.
Vascular endothelial growth factors and receptors involved in angiogenesis and lymphangiogenesis pp. 65-66(2) Author: Alitalo K.
New imaging methods illuminating cellular structure and function pp. 66-66(1) Author: Pepperkok R.
Rationale of the optimal interaction chemotherapy-radiotherapy pp. 66-66(1) Author: Lukas P.
Continuing medical education - The European agenda pp. 66-66(1) Author: Geraghty J.
The impact of surgical training workshops on the outcome in rectal cancer in the population of Stockholm pp. 67-67(1) Authors: Lehander A.; Holm T.; Rutqvist L.E.; Moran B.J.; Heald R.J.; Cedermark B.
Preop chemoradiation (CTRT) +/- postop chemo (CT) in locally advanced rectal cancer. Preliminary results pp. 67-67(1) Authors: Cionini L.; Cartei F.; Valentini V.; Lupattelli M.; Pizzi G.B.; Osti M.; Friso M.L.; Santoni R.; Vidali C.; De Paoli A.
Influence of the interval between pre operative radiotherapy (preop RXT) and surgery on downstaging and sphincter preservation for rectal cancer. The LYON R90 01 randomized trial pp. 67-67(1) Authors: Gerard J.P.; Francois Y.; Nemoz C.; Adeleine P.
In vivo monitoring of tumor microcirculation changes during radiotherapy in patients with rectal carcinomas: preliminary results and possible implications for therapy pp. 67-68(2) Authors: DeVries A.; Griebel J.; Kremser C.; Hoflehner J.; Ofner D.; Debbage P.; Lukas P.
Disseminated tumor cells detected by CK 20 RT-PCR in the blood and the bone marrow of patients with colorectal carcinoma represent an independent prognostic factor pp. 68-68(1) Authors: Vogel I.; Soeth E.; Roder C.; Kremer B.; Kalthoff H.; Henne-Bruns D.
Phase III trial of 5-fluorouracil (5FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in advanced colorectal cancer (ACC) pp. 68-68(1) Authors: Punt C.J.A.; Keizer H.J.; Douma J.; Schuller J.; Skovsgaard T.; ten Napel C.H.H.; Lochs H.; Muller E.W.; Russell L.; Wagener D.J.T.
Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC) pp. 68-68(1) Authors: Rougier P.; Cunningham D.; Roth A.D.; Germa J.R.; James R.D.; Karasek P.; Jandik P.; Iveson T.; Carmichael J.; Gruia G.; Alakl M.; Sibaud D.; Douillard J.Y.
Medical resource use in a phase III trial (SO 14796) of XelodaTM (capecitabine) in previously untreated advanced/metastatic colorectal cancer pp. 68-69(2) Authors: Twelves C.; Van Cutsem E.; Hieke K.; Barker C.; Jamieson C.; Hornberger J.; Garrison L.; Osterwalder B.; Thibault A.
Functional results after total mesorectal excision (TME) in rectal cancer pp. 69-69(1) Authors: Oosterhuis J.W.A.; van Berlo C.L.H.; Reinders J.F.M.
Late side effects of combined treatment modalities in rectal cancer pp. 69-69(1) Authors: Jacob-Heutmann D.; Thilmann C.; Adamietz I.A.; Bottcher H.D.
Liver resection after preop. chemotherapy for colorectal metastases: morbidity and treatment results pp. 69-69(1) Authors: Hohenberger P.; Kilpert B.; Schlag P.M.
Artificial neural network prediction of 5-year survival from colon cancer pp. 69-69(1) Authors: Jessop J.M.; Snow P.; Brandt J.; Bellucco C.; Menck H.R.; Kerr D.J.
Postoperative radiation (RT) and concomitant bolus fluorouracil (FU) with or without additional chemotherapy (CT) as adjuvant treatment in patients with high risk rectal cancer. A randomized phase III study conducted by the Hellenic Cooperative Oncology Group pp. 69-70(2) Authors: Athanassiou E.; Dafni U.; Liaros A.; Briassoulis E.; Samantas E.; Kosmidis P.; Skarlos D.; Pavlidis N.; Fountzilas G.
A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), ''Mayo regimen'', in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC) pp. 70-70(1) Authors: Pozzo C.; Pyrhonen S.; Bodrogi I.; Szanto J.; Kamica-Mlodkowska H.; Starkammar H.; Izso J.; Hansen P.; Kjaer M.; Noel N.; Gruia G.; Barone C.
A pilot study of a feasibility and economic analysis of home based chemotherapy in advanced colorectal cancer pp. 70-70(1) Authors: Ingleby S.; Bamwell J.; Baker J.; Harvey P.; Kerr D.J.; Law V.; Young A.
Thymidylate synthase (TS) protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU) pp. 70-70(1) Authors: Cascinu S.; Aschele C.; Barni S.; Debernardis D.; Baldo C.; Tunesi G.; Catalano V.; Giordani P.; Baldelli A.M.; Catalano G.
Prospective study of adjuvant therapy with monoclonal antibody 17-1A of Dukes' B2/B3-colon carcinoma - Interim analysis of toxicity pp. 70-70(1) Authors: Queisser W.; Franz A.; Hartung G.; Sturm J.; Edler L.; Bornbusch D.; Dietrich G.; Bollinger C.; Gonnermann M.; Wojatschek C.
Once weekly radiotherapy for patients with locally advanced or recurrent rectal cancer pp. 71-71(1) Authors: Tait D.; Glees J.P.; Cook A.; Brooker S.; Norman A.
Adjuvant combined radiochemotherapy in rectal cancer pp. 71-71(1) Authors: Messer P.M.; Welte B.; Suhr P.; Link K.H.; Rottinger E.M.; Beger H.G.
CPT-11 and L-OHP combination versus alternated combination of LV5FU2 + CPT-11/LV5FU2 + L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results pp. 71-71(1) Authors: Becouarn Y.; Mousseau M.; Gamelin E.; Coudert B.; Marceau-suissa J.; Bekradda M.
Folinic acid (FA) and 5-fluorouracil (FU) alone or with irinotecan (CPT-11) for advanced colorectal cancer (ACC): Preliminary results of a randomized phase II trial pp. 71-71(1) Authors: Maiello E.; Giuliani F.; Gebbia V.; Cigolari S.; Fortunato S.; Paoletti G.; Borsellino N.; Lopez M.; Gebbia N.; Colucci G.
Chronomodulated (chrono) infusion of 5-fluorouracil (5-FU) and 1-folinic acid (FA) in 91 patients (pts) with metastatic colorectal cancer: the Regina Elena Cancer Institute experience pp. 71-72(2) Authors: Garufi C.; Aschelter A.M.; Zappala A.; D' Attino R.M.; Antonini C.G.C.; Rosati N.; Nistico C.; Cosimelli M.; Giannarelli D.; Terzoli E.
Qualitative and chronological assessment of toxicities during treatment with raltitrexed ('Tomudex') in 861 patients: implications for patient management pp. 72-72(1) Authors: Garcia-Vargas J.E.; Sahmoud T.; Smith M.P.; Green S.
'Tomudex' (raltitrexed) plus radiotherapy as post-operative treatment or palliative treatment for patients with rectal cancer: phase I studies pp. 72-72(1) Authors: Price P.; James R.; Smith M.
Characterization of genetic subtypes of colorectal cancers pp. 72-72(1) Authors: Csuka O.; Doleschall Z.; Kamory E.; Toth K.; Peter I.; Koves I.; Rahoty P.; Vamosi-Nagy I.; Otto S.
Randomized phase II study of CPT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer (ACC) pp. 72-73(2) Authors: Ulrich-Pur H.; Brugger S.; Kornek G.V.; Fiebiger W.; Haider K.; Kwasny W.; Depisch D.; Kovats E.; Lang F.; Scheithauer W.
Preoperative chemoradiation plus intraoperative presacral electrons in T3-4 Nx M0 primary rectal cancer: early single institution experience pp. 73-73(1) Authors: Calvo F.A.; Cantalapiedra R.; Marcos P.; Del Valle E.; Munoz F.; Garcia-Sabrido J.L.; Gomez M.; Lozano M.A.
A prospective comparison of in-patient versus outpatient DeGramont therapy: using quality of life, acceptability and response measures: a pilot study pp. 73-73(1) Authors: Rowe M.; James R.
Disease oriented treatment of metastatic colorectal cancer (CRC) with dose-dense 5-FU/Folinic acid (FU/FA) combination chemotherapy pp. 73-73(1) Authors: Loeffler T.M.; Droege C.; Lenfers B.H.M.; Hausamen T.U.
Prevention and treatment of carcinomatosis from colorectal malignancy pp. 73-74(2) Author: Sugarbaker P.H.
The prognostic significance of elevated serum CA19-9 level in patients with metastatic colorectal cancer pp. 74-74(1) Authors: Wong A.; Chan A.K.P.
Screening for HNPCC-focussing on families pp. 74-74(1) Authors: Sahm S.; Raedle J.; Schmied A.; Caspary W.; Zeuzem S.
'Tomudex' (raltitrexed) plus 5FU combination treatment for patients with advanced colorectal cancer: a Phase I study pp. 74-74(1) Authors: Mayer S.; Hilger R.; Muller C.; Dohmen D.; Kloeppel R.; Vanhoefer U.; Scheulen M.E.; Seeber S.; Harstick A.
'Tomudex' (raltitrexed) plus 5-fluorouracil: a promising option for the treatment of patients with metastatic colorectal cancer pp. 74-74(1) Authors: Schwartz G.K.; Bertino J.; Kemeny N.; Saltz L.; Kelsen D.K.; Tong W.; Barazzuol J.; Lowery C.; Smith M.
'Tomudex' (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study pp. 75-75(1) Authors: Schulz A.; Garfield D.; Berry W.; Gordon D.; Lowery C.; Smith M.
Second line treatment with irinotecan (CPT11) in patients (pts) with advanced colo-rectal carcinoma (ACRC) resistant to 5FU pp. 75-75(1) Authors: Barcelo J.R.; Rubio I.; Fernandez R.; Mane J.M.; Munoz A.; Abon G.; Fuente N.; Lopez-Vivanco G.
A phase II trial of pre-operative radiation therapy with concomitant 5-FU and sphincter-sparing surgery (preliminary results) pp. 75-75(1) Authors: Ozkan L.; Zorluoglu A.; Yilmazlar T.; Kahraman S.; Engin K.
'Tomudex' (raltitrexed) plus oxaliplatin (Eloxatin) in previously untreated metastatic colorectal cancer (MCRC) patients: an active combination pp. 75-75(1) Authors: Bennouna J.; Seitz J.F.; Paillot B.; Gamelin E.; Francois E.; Conroy T.; Raoul J.L.; Becouarn Y.; Cvitkovic F.B.; Nasca S.; Ychou M.; Jacob J.; Smith M.; Douillard J.Y.; Fandi A.
Preoperative chemoradiation for T3-T4 rectal cancer acute toxicity and tumor response our experience pp. 76-76(1) Authors: Friso M.L.; Loreggian L.; Lora O.; Baiocchi C.; Fasano C.; Pucciarelli S.; Fornasiero A.; Sotti G.
Phase I/II study of oxaliplatin (L-OHP) plus 5-Fluorouracil concurrent with external beam radiotherapy (EBRT) in rectosigmoidcarcinoma pp. 76-76(1) Authors: Ramon y Cajal T.; Rayo S.G.; Calvo E.; Aristu J.J.; Villafranca E.; Canon R.; Moreno M.; Hernandez J.L.; Azinovic I.
Expression of the erbB family in colorectal adenocarcinoma pp. 76-76(1) Authors: Kapitanovic S.; Radosevic S.; Ferencic Z.; Spaventi S.; Pavelic K.; Spaventi R.
Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation pp. 76-76(1) Authors: Avital S.; Haddad R.; Troitsa A.; Kashtan H.; Brazovsky E.; Gitstein G.; Skornick Y.; Schneebaum S.
Mutations in repeated sequences within cancer genes in sporadic replication error positive colorectal cancers pp. 76-76(1) Authors: Fiorente P.; Cariola F.; Nanna P.; Gristina R.; Leo S.; Gentile M.
Severe toxicity of a standard 5-FU/Leucovorin combination in patients with colorectal cancer: a prospective study pp. 77-77(1) Authors: Tsalic M.; Bar-Sela G.; Menashe N.; Vizel B.; Haim N.
Tyrosine phosphatases in integrin-mediated cell adhesion to collagen under static and dynamic flow conditions pp. 77-77(1) Authors: Haier J.; Nasralla M.; Nicolson G.L.
Randomized trial of 5-Fluorouracil (5-FU)-Levamisol (LEV) versus 5FU-LEV-Leucovorin (LV) in patients with colorrectal cancer stage II and III. Eigth years results pp. 77-77(1) Authors: Murias A.; Aguiar J.; Bohn U.; Molano F.; Almenarez J.; Garcia I.; Diaz-Chico J.C.
Relationship between s-phase fraction and clinical outcome after surgery for colorectal carcinoma pp. 77-77(1) Authors: Cianchi F.; Balzi M.; Becciolini A.; Faraoni P.; Pucciani F.; Perigli G.; Bechi P.; Palomba A.; Ciancio G.; Cortesini C.
Oral uracil/tegafur (UFT) plus leucovorin (LV) in patients with metastatic colorectal cancer (CRC) pp. 78-78(1) Authors: Goker E.; Aykan N.F.; Serdengecti S.; Gunel N.; Alakavuklar M.; Icli F.; Yucel I.; Uskent N.; Arpaci F.; Firat D.
Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas pp. 78-78(1) Authors: Seong J.; Chung E.; Kim H.; Kim G.; Kim N.; Sohn S.; Min J.; Suh C.
Adjuvant 5-FU based therapy for colorectal cancer pp. 78-78(1) Authors: Munoz A.; Rubio I.; Mane J.M.; Barcelo J.R.; Fernandez R.; Abon G.; Fuente N.; Lopez-Vivanco G.
Fas-APO1 (CD95+) expression on peripheral blood T lymphocytes (Ly) before and after surgery in colorectal cancer (CRC) patients pp. 78-78(1) Authors: Donina S.; Engele L.; Jaunalksne I.; Zakenfelds G.; Citovica M.; Klestrupe I.
A bi-modality treatment of hepatic arterial therapy (HAT) of unresectable isolated colorectal liver metastases (CLM). Our experience pp. 78-79(2) Authors: Jafelice G.; Pittureri C.; Mazziotti A.; Jovine E.; Grazi G.L.; Golfieri R.; Giampalma M.; Piccinini E.; Di Stefano A.; Piana E.; Martoni A.; Pannuti F.
Phase I of CPT-11 (CAMPTO(R)) combined with 5-FU/folinic acid (FA) nordic schedule in first line metastatic colorectal cancer (CRC) pp. 79-79(1) Authors: Ristamaki R.; Glimelius B.; Linne T.; Boussard B.; Oulid-Aissa D.; Pyrhonen S.
CAMPTO(R) (CPT-11) combined with different schedules of bolus 5-FU in 1st line treatment of metastatic colorectal cancer pp. 79-79(1) Authors: Graeven U.; Ridwelski K.; Manns M.P.; Espana P.; Carlsson G.; Borner M.; Boussard B.; Oulid-Aissa D.; Hemmers H.; Schmiegel W.H.
Advanced colorectal cancer (ACC): impact of chronotherapy (chrono) on patients' (pts) quality of life (QoL) pp. 79-79(1) Authors: Pugliese P.; Garufi C.; Perrone M.; Aschelter A.M.; Zappala A.; Giannarelli D.; Cosimelli M.; Terzoli E.
The peculiarity HLA-allels and HLA-lymphocyte phenotypes in the patients of Uzbek population suffering from colorectal cancer pp. 80-80(1) Authors: Tukhfatullina-Gainullina Z.; Muhammadobidov S.; Rakhimova D.; Gildieva M.
Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5fu pp. 80-80(1) Authors: Beretta G.D.; Cascinu S.; Zaniboni A.; Ratti R.; Giordani P.; Catalano V.; Martignoni G.; Barni S.; Frontini L.; Labianca R.
Oxaliplatin, 5-FU and folinic acid (OFFA) as II-line chemotherapy in advanced colorectal cancer pp. 80-80(1) Authors: Tassinari D.; Panzini I.; Pasquini E.; Desiderio F.; Drudi G.; Fattori P.P.; Gianni L.; Oliveno G.; Tononi A.; Ravaioli A.
'Tomudex' (raltitrexed) has a manageable toxicity profile in elderly patients with metastatic colorectal cancer pp. 80-80(1) Authors: Facchini T.; Genet D.; Berdah J.F.; Nouyrigat P.; Dutin J.P.; Laplaige P.; Smith M.; Haguenauer D.
Preoperative radiotherapy for advanced lower rectal cancer-combination of external and high-dose-rate intraluminal radiotherapy pp. 80-81(2) Authors: Horikawa N.; Yoshimura H.; Tamamoto T.; Uto F.; Tsuji Y.; Ohishi H.; Asakawa I.; Uchida H.; Fujii H.; Nakano H.
A phase II study of alternating cycles of CPT-11 and high-dose 48 hour infusion 5-FU in combination with leucovorin (HD-5-FU/LV) in no selective patients with metastatic colorectal cancer (MCRC) pp. 81-81(1) Authors: Rosati G.; Bilancia D.; De Santis S.; Dinota A.; Rossi A.; Manzione L.
Phase-II-study of a 24-h infusion with 5-fluorouracil (5-FU) and simultaneous sodium-folinic acid in the first-line-treatment of advanced colorectal cancer: interim analysis pp. 81-81(1) Authors: Hofheinz R.; Hartung G.; Wein A.; Riedel C.; Kuhfahl J.; Rost A.; Brecht A.; Bolte R.; Fritze D.; Keilholz U.; Kreuser E.D.; Queisser W.
The distribution of polymorphic enzymes in colon cancer case pp. 81-81(1) Authors: Romer H.C.; Thier R.; Reckwitz T.; Geller F.; Buschendorf I.; Lohlein D.; Golka K.
Oxaliplatin (OX) after irinotecan (IRI): antitumour activity and clinical benefit of 3rd and higher line chemotherapy with ox for patients (pts) with metastatic colorectal cancer (MCC) after failure of IRI pp. 81-81(1) Authors: Kretzschmar A.; Metzger J.; Thuss-Patience P.C.; Kaufmann C.C.; Wilhelm M.; Kroning H.; Schumacher H.; Reichardt P.
Adjuvant trial in melanoma patients comparing rIFN- to rIFN- to Iscador to a control group after curative resection of high risk primary (=<3 MM) or regional lymphnode metastasis (EORTC 18871) pp. 82-82(1) Authors: Kleeberg U.R.; Brocker E.B.; Lejeune F.; Chartier C.; Egger C.; Marsden J.; Ruiter D.; Suciu S.
QUASAR: a UKCCCR study of adjuvant chemotherapy (CT) for colorectal cancer pp. 82-82(1) Authors: Gray R.G.; Kerr D.J.; McConkey C.; Williams N.S.
Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy - A phase III EORTC study pp. 82-82(1) Authors: Bolla M.; Collette L.; Gonzalez D.; Warde P.; Dubois J.B.; Mirimanoff R.; Storme G.; Bernier J.; Kuten A.; Pierart M.
Randomized trial of chemoprevention with vitamin A and N-acetylcysteine in patients with cancer of the upper and lower airways: the EUROSCAN study pp. 82-82(1) Authors: van Zandwijk N.; Pastorino U.; de Vries N.; Dalesio O.; van Tinteren H.
Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5 pp. 83-83(1) Authors: Jakesz R.; Hausmaninger H.; Samonigg H.; Kubista E.; Depisch D.; Fridrik M.; Stierer M.; Gnant M.; Steger G.; Kolb R.; Jatzko G.; Hofbauer F.; Reiner G.; Steindorfer P.
Adjuvant treatment of premenopausal breast cancer with zoladex and tamoxifen: results from randomised trials by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, The Stockholm Breast Cancer Study Group, the South East Sweden Breast Cancer Group and Gruppo Interdisciplinare Valutazione Intervention Oncologia (GIVIO) pp. 83-83(1) Author: Nordenskjold B.
Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate pp. 83-83(1) Authors: Diel I.J.; Lichinitser M.R.; Body J.J.; Schlosser K.; Moecks J.; Cavalli F.; Dornoff W.; Gorbunova V.A.; McCloskey E.; Weisz J.; Kanis J.A.
Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin pp. 83-83(1) Authors: Mouridsen H.T.; Andersen J.; Andersson M.; Dombernowsky P.; Ejlertsen B.; Rose C.; Sorensen P.G.; Sandberg E.; Andersen K.W.; Jensen M.-B.; Bengtson N.O.; Bergh J.; Nordenskjold B.
Survival advantage of exemestane (EXE, Aromasin(R)) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study pp. 84-84(1) Authors: Bajetta E.; Dirix L.Y.; Fein L.E.; Jones S.E.; Cervek J.; Kaufmann M.; Fowst C.; Polli A.; di Salle E.; Massimini G.
Estrogen receptor-beta: a new form of estrogen receptor in breast cancer pp. 84-84(1) Authors: Cullen R.; Maguire T.M.; McDermott E.; O'Higgins N.; Duffy M.J.
HER2/neu as a predictive factor in breast cancer pp. 84-84(1) Authors: Piccart M.; Hamilton A.
Cytokeratin (CK)-positive bone marrow micrometastases (BMM) and survival in stage I-III breast cancer pp. 84-84(1) Authors: Braun S.; Pantel K.; Janni W.; Hepp F.; Kentenich C.R.M.; Muller P.; Gastroph S.
Micrometastases in sentinel node in breast cancer pp. 85-85(1) Authors: Barbera D.; Ellis I.O.; Geraghty J.G.
Mammographic size of ductal carcinoma in situ (DCIS) does not predict the presence of an invasive focus pp. 85-85(1) Authors: Wahedna Y.; Evans A.J.; Proder S.E.; Blamey R.W.; Ellis I.O.; Geraghty J.G.
Local recurrence (LR) after breast-conserving therapy (BCT) in node-negative premenopausal patients. Risk factors and influence of Peri-operative Chemotherapy (PeCT); an EORTC Breast Cancer Cooperative Group Study pp. 85-85(1) Authors: Elkhuizen P.H.M.; van Slooten H.J.; Clahsen P.C.; Hermans J.; van de Velde C.J.H.; van den Broek L.C.J.M.; van de Vijver M.J.
Individualised survival prediction in breast cancer (BC) based on nation-wide follow-up data: the finprog study pp. 85-85(1) Authors: Joensuu H.; Lundin J.; Lundin M.; Holli K.; Pylkkanen L.; Turpeennemi-Hujanen T.
Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT) pp. 86-86(1) Authors: De Cremoux P.; Dieras V.; Le Doussal V.; Vincent-Salomon A.; Tubiana-Hulin M.; Pierga J.-Y.; Spyratos F.; Magdelenat H.; Pouillart P.
Her 2 positivity and ER negativity predicts the complete pathological response of breast cancers treated with primary docetaxel pp. 86-86(1) Authors: Payne S.; Miller I.D.; Smith I.C.; Heys S.D.; Walker L.G.; Anderson J.; Hutcheon A.W.; Ah-See A.K.; Eggleton S.P.H.; Eremin O.
Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast pp. 86-86(1) Authors: Loibl S.; von Minckwitz G.; Weber S.; Schini-Kerth V.; Sinn H.P.; Hildenbrand R.; Mulsch A.; Fichtlscherer B.; Kaufmann M.
Immuncytochemical detection of cytokeratin (CK)-positive micro-metastases in lymph nodes (LN) and bone marrow (BM) from node-negativ breast cancer patients with stage I-II disease pp. 86-87(2) Authors: Cevatli B.S.; Assemi C.; Trimpl A.; Braun S.
A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood pp. 87-87(1) Authors: Aerts J.; Wynendaele W.; Paridaens R.; Christiaens M.R.; Van den Bogaert W.; van Oosterom A.T.; Vandekerckhove F.
HER2 interaction with intermediate filament proteins and the influence on prognosis in breast cancer pp. 87-87(1) Authors: Fuchs I.; Danneschewski S.; Buhler H.; Schaller G.
C-ERB-B2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs single-agent epirubicin in stage I-II breast cancer (BC) patients pp. 87-87(1) Authors: Colozza M.; Gori S.; Mosconi A.M.; Bucciarelli E.; Bisagni G.; Rodino C.; Bian A.R.; Sabbatini R.; Mazzocchi
Predictors of axillary lymph node involvement in breast cancer <20 mm pp. 87-88(2) Authors: Krause A.; Gerber B.; Muller H.; Reimer T.; Richter D.; Markowitzky J.; Friese K.
Clinico-pathological characteristics of breast cancer associated with thyroid disease pp. 88-88(1) Authors: Montemurro F.; Cristofanilli M.; Smith T.; Asmar L.; Hortobagyi G.N.
Bcl-2 expression, cell differentiation and survival in primary breast cancer pp. 88-88(1) Authors: Vandebroek A.; Makar A.; Joosens E.; Van Leuven H.; Declercq S.; Beelaers W.; Van den Weyngaert D.; Gerris J.; Becquart D.; Kockx M.
Fine needle aspiration is associated with hematogenous dissemination of breast cancer cells as determined by RT-PCR pp. 88-88(1) Authors: Hu X.C.; Chow L.W.C.
Local Recurrence (LR) after Breast Conserving Therapy (BCT); risk factors predicting for subsequent distant metastasis pp. 88-89(2) Authors: Elkhuizen P.H.M.; Hermans J.; Leer J.W.H.; van den Broek L.C.J.M.; van de Vijver M.J.
Quantitation of c-erbB-2 in primary breast cancer allows identification of a further poor prognostic group pp. 89-89(1) Authors: Chong D.; Cooke T.G.; Reeves J.R.; George W.D.; Mallon E.A.; Ozanne B.; Stanton P.
Prognostic impact of extended extracapsular component (EEC) in involved lymph nodes (LN) in primary breast cancer (BC) pp. 89-89(1) Authors: Kahlert S.; Boettcher B.; Lebeau A.; Bauerfeind I.; Nestle-Kraemling C.; Untch M.
The study of breast cancer metastases to the specific group of the axillary lymph nodes pp. 89-89(1) Authors: Stanislawek A.; Kurylcio L.
Overexpression of p27 in relation to p53 and clinicopathologic variables in node-positive breast cancer pp. 89-89(1) Authors: Tsuchiya A.; Zhang G.-J.; Endo Y.; Nakamura I.; Watanabe T.; Kimijima I.; Takenoshita S.
Fatty acid synthase expression in breast carcinoma patients. Correlation with hormone receptors pp. 90-90(1) Authors: Nakamura I.; Kimijima I.; Zhang G.J.; Onogi H.; Endo Y.; Suzuki S.; Tuchiya A.; Takenoshita S.
Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance pp. 90-90(1) Authors: Asgeirsson K.S.; Jonasson J.G.; Tryggvadottir L.; Olafsdottir K.; Ingvarsson S.; Ogmundsdottir H.M.
Plasminogen activator inhibitor type 2: expression and prognostic value in primary breast cancer pp. 90-90(1) Authors: Fersis N.; Ruja A.; Kuo Y.-L.; Friese H.; Thron S.; Bastert G.; Wallwiener D.
Quantitative analysis of circulating tumour cells in breast cancer patients using reverse transcriptase polymerase chain reaction pp. 90-90(1) Authors: Wong I.H.N.; Yeo W.; Chan A.T.; Johnson P.J.
Breast cancer: does tumour location influence survival and cosmesis? Experience from 644 patients (1984-1995) pp. 90-91(2) Authors: Hammer J.; Track C.; Seewald D.H.; Zoidl J.P.; Labeck W.; Putz E.; Gruy B.
Relationship between insulin-like growth factor 1 (IGF-1), prolactin (PRL), human growth hormone (hGH) and steroid receptors in breast cancer patients pp. 91-91(1) Authors: Delgado L.; Alonso O.; Alonso I.; Artagaveytia N.; Alvarez B.; Sabini G.; Roca R.; Muse I.M.
Expression of cyclin dependent kinase inhibitor protein p27kip in localized invasive ductal carcinoma of the breast pp. 91-91(1) Authors: Kourea H.; Koutras A.; Zolota V.; Marangos M.; Tzorakoeleutherakis E.; Koukouras D.; Kalofonos H.
Circulating antibodies against a breast tumor antigen pp. 91-91(1) Authors: Pasquinelli R.; Capasso I.; D'Aiuto M.; Barba P.; Anzisi A.M.; D'Aiuto G.; Guardiola J.
Correlation between proliferating cell nuclear antigen (PCNA) and p53 protein expression in breast carcinomas. Can they have a prognostic value? pp. 91-91(1) Authors: Lazar L.; Berindan I.; Balacescu O.; Risca R.; Neagoe E.; Lazar G.
Increased E-cadherin and keratin 18 expression is associated with better prognosis in patients with human breast cancer pp. 91-92(2) Authors: Glienke Y.; Fuchs I.; Buhler H.; Lorenz A.; Opri F.; Voss H.; Schaller G.
Immunohistochemical studies on oncogene products (C-erbB-2) and p53 protein in human breast cancer: is it significant for tumor evolution? pp. 92-92(1) Authors: Lazzr L.; Berindan I.; Balacescu O.; Neagoe E.; Risca R.; Lazar G.
Possible causes of breast cancer in women working at coke-chemical factory (CCF) pp. 92-92(1) Authors: Gurieva V.A.; Gonopolskaya T.L.; Ivanov E.G.
Determination of fibrin D-dimers in patients with breast cancer after cytotoxic chemotherapy pp. 92-92(1) Authors: Koufos C.; Tsavaris N.; Kosmas C.; Travlou A.
Prognostic value of cathepsin D in breast cancer (BC) patients pp. 92-92(1) Authors: Adrover E.; Maestro M.L.; Sanz-Casla T.; Del Barco V.; Valor R.
Influence of prognostic factors on overall and disease free survival in male patients with primary carcinoma of the breast pp. 92-93(2) Authors: Stranzl H.; Prettenhofer U.; Mayer R.; Quehenberger F.; Willfurth P.; Guss H.; Hackl A.
Male breast cancer - New prognostic factors? pp. 93-93(1) Authors: Afonso N.; Pereira D.; Silva C.; Lopes C.
Tomotherapy with peacock: The University of California, Irvine experience pp. 93-93(1) Authors: Al-Ghazi M.; Ammirati M.; Kuo J.; Qian Y.; Ramsinghani N.; Yakoob R.
Stereotactic radiotherapy in the treatment of ocular melanoma pp. 93-93(1) Authors: Jaywant S.; Michaels H.; Laperriere N.
Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned photon and a standard photon technique pp. 93-94(2) Authors: Fuss M.; Hug E.B.; Schaefer R.A.; Nevinny M.; Slater J.D.
Dosimetric imrovements following 3-D planning of tangential breast irradiation pp. 94-94(1) Authors: Aref A.; Thornton D.; Youssef E.; He T.; Tekyi-Mensah S.; Denton L.; Ezzell G.
Commissioning and clinical use of a micro multi-leaf collimator for conformal radiosurgery pp. 94-94(1) Authors: Schlenger L.; Bohsung J.; Cosgrove V.P.; Groll J.; Jahn U.; Kaiser A.; Pfaender M.; Stuschke M.; Budach V.; Wurm R.E.
A comparative analysis of electronic portal image quality for patients receiving whole pelvic irradiation pp. 94-94(1) Authors: Van Den Heuvel F.; Strowbridge A.; Han I.; Chungbin S.; Ragan D.
Impact of new technology on radiation therapy treatment deviations at TSRCC pp. 94-94(1) Authors: Robson S.; Pegler R.; Danjoux C.; Chow E.; Franssen E.; Thomas G.
Rectal in-vivo dosimetry in fractionated brachytherapy of cervix cancer with HDR-Fletcher-Applicator (HDR-FA) pp. 95-95(1) Authors: Rahim H.; Kametriser G.; Sedlmayer F.; Brandis M.G.; Merz F.; Deutschmann H.; Wurstbauer K.; Kogelnik H.D.
The use of an immobilisation system in the treatment of prostate cancer with conformal radiotherapy - A prospective randomised trial pp. 95-95(1) Authors: Nutting C.; Khoo V.; Walker V.; Norman A.; Dearnaley D.P.
Treatment of malignant pericardial effusion with 32P-colloid pp. 95-95(1) Authors: Dempke W.; Kegel T.; Voigt W.; Buchele T.; Grothey A.; Schmoll H.J.; Firusian N.
Stereotactic irradiation of uveal melanoma at a 6 MV-linear accelerator - Technical considerations concerning movement verification by video recording pp. 95-95(1) Authors: Kren G.; Dieckmann K.; Zehetmayer M.; Bogner J.; Potter R.
Comparison of radiation therapy planning for proton- and photon treatment of pediatric Wilms' tumors pp. 95-96(2) Authors: Nevinny M.; Hug E.B.; Fuss M.; Miller D.W.; Lukas P.; Slater J.D.
Photodynamic therapy (PDT) in superficial malignomas using visible light and various photosensitizers plus minus hyperthermia pp. 96-96(1) Authors: Kolbabek H.; Jindra R.H.; Kubin A.; Alth G.; Dobrowsky W.
Intensity modulated radiotherapy (IMRT) for carcinoma of the thyroid and parotid gland pp. 96-96(1) Authors: Nutting C.; Convery D.; Rowbottom C.; Cosgrove V.; Dearnaley D.P.; Henk J.M.; Harmer C.; Webb S.
Patient diode dosimetry for electron beam treatments: clinical implementation and dosimetric considerations pp. 96-96(1) Authors: Yaparpalvi R.; Fontenla D.P.; Vikram B.
Pulsed dose rate brachytherapy in the treatment of head and neck carcinoma pp. 96-96(1) Authors: Pokrajac B.; Knocke T.H.; Fellner C.; Seitz W.; Schmid R.; Potter R.
Treatment planning for the second stereotactic radiosurgery utilizing the previous target reconstructed by image fusion pp. 97-97(1) Authors: Shibayama C.; Nakazawa M.; Masubuchi J.; Sakai O.; Sugawara T.; Shinoda S.; Hashimoto M.; Masuzawa T.; Furuse M.
'Recumbent position' and Stanford methods of total skin electron irradiation in the treatment of mycosis fungoides: comparison of long-term side effects pp. 97-97(1) Authors: Kuten A.; Rosenblatt E.; Bar-Deroma R.; Toffler E.; Cederbaum M.; Stein M.E.
Effectivity of lead blockages of the lung in tangential breast irradiation pp. 97-97(1) Authors: Stegmaier P.; Maurer U.; Kaessner J.; Steil V.; Georgi M.
Virtual two dimensional (2D) step wedge for film dosimetry calibration for megavoltage photon beams pp. 97-97(1) Author: Meng J.
NSCLC: Dose escalation by target splitting with asymmetric collimation pp. 97-98(2) Authors: Wurstbauer K.; Deutschmann H.; Kranzinger M.; Merz F.; Rahim H.; Sedlmayer F.; Kogelnik H.D.
A simple technique for the optimization of the dose distribution in the lower neck and upper thoracic area pp. 98-98(1) Authors: Kopp M.; Rahim H.; Deutschmann H.; Kogelnik H.D.
Subcutaneous amifostin during fractionated radiotherapy: a randomized phase II study in pelvic tumours pp. 98-98(1) Authors: Koukourakis M.I.; Frangiadaki C.; Stavroulaki A.; Ratalis G.
Total body irradiation (TBI) before bone marrow transplantation (BMT): technique and acute toxicity pp. 98-98(1) Authors: Szekely J.; Fabry L.; Forgacs G.; Kontra G.; Petranyi J.; Nemeth G.
External beam radiotherapy of intraocular metastases pp. 98-98(1) Authors: Bajcsay A.; Toth J.; Recsan Z.; Kontra G.; Horvath A.; Nemeth G.
Procedures of radiotherapy with boron neutron capture reaction at the Petten irradiation facility pp. 98-99(2) Authors: Hideghety K.; Sauerwein W.; Vroegindeweij C.; Moss R.L.; Watkins P.; Garbel S.; Rassow J.
The elekta multileaf collimator (MLC). A universal soldier made to conform pp. 99-99(1) Author: Welch M.
HDR boost brachytherapy with flexible implants in breast cancer pp. 99-99(1) Authors: Barbera L.; Casas O.; Terrier F.; Giacomi N.; Vigo S.; Pascuale R.; De Angelis C.; Negri H.; Menendez P.
Past, present and future trends of boron neutron capture therapy (BNCT) pp. 99-99(1) Authors: Sauerwein W.; Hideghey K.; Moss R.; Busse P.; Harling O.; Zamenhoff R.; Coderre J.; Nakagawa Y.; Pignol J.-P.
Hyperfractionated body stereotactic radiosurgery (BSR) pp. 99-99(1) Authors: Qian G.; Lowry J.; Silverman P.; Grosman I.; Lombardi E.; Volpicella F.; Lederman G.
Advanced on-time treatment planning for intraoperative radiotherapy (IORT) pp. 99-100(2) Authors: Deutschmann H.; Sedlmayer F.; Kopp M.; Rahim H.; Merz F.; Kopp P.; Hutter J.; Waclawiczek H.W.; Gruber W.; Kogelnik H.D.
Variation in dose distribution for breast radiotherapy: a trial based quality assurance programme in the UK pp. 100-100(1) Authors: Deighton A.; Winfield E.A.; Venables K.; Aird E.G.A.; Hoskin P.J.
3D planning for tangential breast irradiation: Feasible and relevant? pp. 100-100(1) Authors: Van Gestel D.; Vanregemorter J.; De Ost B.; Vanderkam S.; Meijnders P.; Van den Weyngaert D.
Total body irradiation - Prospective evaluation of early side effects pp. 100-100(1) Authors: Obert K.; Mose S.; Jacob-Heutmann D.; Damrau M.; Ramm U.; Rischke H.C.; Fauth F.; Bottcher H.D.
Is the vaginal rod an accurate method to localise the vaginal apex? pp. 100-100(1) Authors: Wiggenraad R.; Coerkamp E.; Tamminga R.; Wiersma T.; Sorge A.v.
Intraoperative radiation therapy (IORT) and chemotherapy in treatment of urinary bladder cancer pp. 101-101(1) Authors: El-Wahidi G.; Ashamallah A.; Eita M.; Teima S.; Denewer A.; Gomha M.
Preoperative radiotherapy of schistosomal bladder cancer. Prospective randomised study pp. 101-101(1) Authors: El-Wahidi G.; Ghoneim M.A.; Saker H.; Fouda M.A.
High-dose-rate brachytherapy after exernal beam irradiation in palliative treatment of squamous cell carcinoma of the esophagus pp. 101-101(1) Authors: Eickhoff A.S.; von Lieven H.; Aydin H.; Eickhoff J.C.
Dose optimisation of boost irradiation using electron beam in breast carcinoma pp. 101-101(1) Authors: Okutan M.; Kemikler G.; Ozbilen S.; Cakir A.; Aslay I.
Re-evaluation of the study design of the phase I clinical trial with BNCT for patients with glioblastoma at the High Flux Reactor Petten (EORTC protocol 11961) pp. 101-101(1) Authors: Hideghety K.; Sauerwein W.; de Vries M.; Wanders J.; Husing J.; Moss R.; Rassow J.; Gabel D.
Comparative study between respiratory gated conventional 2-D plan and 3-D conformal plan for predicting radiation hepatitis pp. 101-102(2) Authors: Lee S.W.; Kim G.E.; Chung K.S.; Lee C.G.; Seong J.; Suh C.O.
Measurement of patient entry and exit doses during total body irradiation pp. 102-102(1) Authors: Damrau M.; Ramm U.; Manegold K.H.; Mose S.; Rischke H.C.; Jacob-Heutmann D.; Obert K.; Rahl C.G.; Bottcher H.D.
Intraoperative high dose rate interstitial irradiation of hepatic metastases pp. 102-102(1) Authors: Villalba S.R.; Ortega M.S.; Mateo A.; Ortega J.; Castell T.; Valderrabamo S.; Lenni A.
The impact a multileaf collimator (MLC) may have on a departments confidence and quality assurance pp. 102-102(1) Author: Welch M.
Concurrent radiotherapy and chemotherapy with topotecan and stealth liposomal doxorubicin for the treatment of locally advanced pelvic tumours pp. 102-102(1) Authors: Koukourakis M.I.; Chaldeopoulos D.; Lyraraki E.; Varveris C.
Subcutaneous administration of Amifostine in patients treated with radiotherapy. A preliminary report pp. 102-103(2) Authors: Ravo V.; Guida C.; Silvestro G.; Spena F.R.; Elmo M.; Pecori B.; Frezza P.
Antiangiogenic and antitumor effect of VEGF antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in human colon cancer pp. 103-103(1) Authors: Ciardiello F.; Bianco R.; Damiano V.; Caputo R.; De Placido S.; Fontanini G.; Agrawal S.; Mendelsohn J.; Bianco A.R.; Tortora G.
Free circulating vascular endothelial growth factor (VEGF) is detectable only in small tumours of the WAG/Rij rat rhabdomyosarcoma tumour model pp. 103-103(1) Authors: Wynendaele W.; Landuyt W.; van Oosterom A.T.; Lambin P.
Plasma D-dimer levels, serum VEGF, b-FGF and IL-6 in metastatic breast cancer (MBC): correlation with tumour load and response to therapy pp. 103-103(1) Authors: Dirix L.; Weytjens R.; Salgado R.; Benoy I.; Vermeulen P.; Prove A.; Van Dam P.; Lemmens J.
In vitro differentiation of endothelial cells (EC) from AC133-positive progenitor cells pp. 103-104(2) Authors: Gehling U.M.; Ergun S.; Schuch G.; Schafhausen P.; Kilic N.; Schafer B.; Hossfeld D.K.; Fiedler W.
Genomic instability in bronchial lavage specimens from individuals with no evidence of lung cancer: an early detection marker? pp. 104-104(1) Authors: Field J.K.; Liloglou T.; Xinarianos G.; Turnbull L.; Walshaw M.
Tumour cells can eliminate amplified genes pp. 104-104(1) Authors: Ambros A.I.; Luegmayr A.; Rumpler S.; Hattinger C.M.; Kovar H.; Gadner H.; Ambros P.F.
Inhibition of NF-kB activation confers sensitivity to TNFa by impairment of cell-cycle progression in human glioma cells pp. 104-104(1) Authors: Otsuka G.; Nagaya T.; Saito K.; Mizuno M.; Yoshida J.; Seo H.
Death receptors in etoposide treated lymphoma cells pp. 104-104(1) Authors: Mihalik R.; Sebestyen A.; Barna G.; Bauer P.; Kopper L.
'Invading edge vs. inner' vascularisation: angio-genic and angio-preserving activity in non-small cell lung cancer (NSCLC) pp. 105-105(1) Authors: Giatromanolaki A.; Koukourakis M.I.; Sivridis E.; O'Byrne K.; Garter K.C.; Harris A.L.
Tumour angiogenesis and response in combined modality treatment of head and neck cancer pp. 105-105(1) Authors: Dobrowsky E.; Lang S.; Dobrowsky W.
The importance of timing in thermochemotherapy with tubulin inhibitors pp. 105-105(1) Authors: Eikesdal H.P.; Dahl O.
Serum erythropoietin level in anemic cancer patients pp. 105-105(1) Authors: Ozguroglu M.; Demir G.; Demirelli F.; Molinas-Mandel N.; Buyukunal E.; Serdengecti S.; Berkarda B.
Selective tumor cell kill by alkyl-lysophospholipids pp. 106-106(1) Authors: Zerp S.F.; Ruiter G.A.; Bartelink H.; van Blitterswijk W.J.; Verheij M.
Involvement of cytoskeleton in dynamic adhesion of HT-29 cells to extracellular matrix under flow conditions pp. 106-106(1) Authors: Haier J.; Nasralla M.; Nicolson G.L.
Cross-talk between c gamma RIIA and c gamma RIIc on human natural killer cells pp. 106-106(1) Authors: Popescu I.; Hirt M.; Calugaru A.; Baiu D.; Manciulea M.; Metes D.; Morel P.; Herberman R.; Sulica A.
Quantification and characterization of micro tumor load: an option for monitoring adjuvant and palliative disease pp. 106-106(1) Authors: Habets L.; Grotius O.; Doll S.; Lippok B.; Gajewsky M.; Braun P.; Knechten H.
Analysis of telomerase activity in physiological and pathological endometrial tissues pp. 106-107(2) Authors: Jimenez E.; Garcia-Foncillas J.; Guzman M.; Andion E.; Huarriz M.; Okroujnov I.; Errasti T.; Jurado M.; Schneider J.; Brugarolas A.
MUC1 mucin for the detection of epithelial-derived ovarian cancer cells in peripheral blood pp. 107-107(1) Authors: Obermair A.; Stimpfl M.; Schmid B.; Tong D.; Schiebel I.; Leodolter S.; Zeillinger R.
Matrix metalloproteinase expression in normal, inflammed and malignant mesothelial tissues pp. 107-107(1) Authors: Edwards J.G.; Walker R.A.; McLaren J.; Waller D.A.; Steward W.P.; O'Byrne K.J.
Vascular endothelial growth factor (VEGF) in sera of patients with cervical cancer and the impact of platelets pp. 107-107(1) Authors: Hansgen G.; Becker A.; Hintner I.; Dunst J.
Creation of a stage by stage diagnostics system of malignant tumors pp. 107-107(1) Authors: Petrov S.; Balatenko N.; Khasanov R.
Genistein inhibits initial dynamic adhesion of HT-29 cells to extracellular matrix under flow conditions pp. 107-108(2) Authors: Haier J.; Nasralla M.; Nicolson G.L.
Signal transduccion pathways activated by antineoplasic drugs and their role in apoptosis pp. 108-108(1) Authors: Sanchez-Perez I.; Perona R.
Angiogenesis of tumors in childhood. Preliminary study pp. 108-108(1) Authors: Moschovi M.; Tsangaris G.T.; Vamvoukakis J.; Anastasiou A.; Van Vliet-Konstantinidou C.; Tzortzatou-Stathopoulou F.
Lymphocyte subpopulations in patients with multiple primary tumors pp. 108-108(1) Authors: Robinson E.; Segal R.; Struminger L.; Faraggi D.; El'ad-Yarum R.; Mekori T.
Gain of an intracrine, proliferative loop involving FGF-2 and FGF-receptors in human non-small cell lung cancer (NSCLC) cells pp. 108-108(1) Authors: Berger W.; Setinek U.; Elbling L.; Mohr T.; Kindas-Mugge I.; Micksche M.
Effect of the conditioned medium (CM) of bone marrow (BM) fibroblast colony forming units (CFU-F) from patients with solid tumor on the growth of normal CFU-F pp. 108-109(2) Authors: Chasseing N.; Honegger A.; Bordenave R.; Hoffer E.; Shanley C.; Rumi L.
Efficient autologous inhibition of tumor growth in a murine model of renal carcinoma pp. 109-109(1) Authors: Hugenschmidt H.; Wittig C.; Unger C.; Marme D.; Drevs J.
K+-efflux modulation of cisplatin-induced apoptosis and cytotoxicity to cultured mesothelioma cells pp. 109-109(1) Authors: Marklund L.; Henriksson R.; Grankvist K.
In-vivo growth modulation of FaDu-xenografts in nude mice with 2-methoxyoestradiol and oestradiol pp. 109-109(1) Authors: Claszen J.; Budach W.; Bamberg M.
p53 protein expression and proliferative activity in renal cell carcinomas pp. 109-109(1) Authors: Ioakim-Liossi A.; Pantazopoulos D.; Karakitsos P.; Athanassiadou P.; Stergiou E.; Karkabassi A.; Athanassiades P.; Davaris P.
Differental loss E-cadherin in breast carcinomas pp. 110-110(1) Authors: Berindan I.; Balacescu O.; Risca R.; Neagoe E.
The TNF level in plasma and in primary tumor conditional medium in gastric cancer patients pp. 110-110(1) Authors: Hipp I.; Volodko N.; Barylka V.; Piddubnyak V.; Bilynsky B.
Apoptotic effects of taxol and radiation on the intestinal kript cells of swiss-albino mice pp. 110-110(1) Authors: Ozkan L.; Ozuysal S.; Egeli U.; Balim S.; Tunca B.; Aydemir N.; Cecener G.; Engin K.
Expression on tumors and its metatases of platelet endothelial cell adhesion (PECAM-1), a molecule involvement in transendothelial cell migration and angiogenesis pp. 110-110(1) Authors: De La Haba J.; Lucena C.; Munoz E.; Canale M.; Macho A.; Barneto I.; Aranda E.
Fibronectin in cell adhesion. It's expression in breast tumors pp. 110-111(2) Authors: Berindan I.; Balacescu O.; Risca R.; Neagoe E.
Dominant properties for the suppression of development of preneoplastic foci in the liver of carcinogen resistant inbred DRH strain rats pp. 111-111(1) Authors: Higashi K.; Yan Y.; Denda A.; Konishi Y.
The standards, options and recommendations (SOR) project for the management of childhood cancer pp. 111-111(1) Authors: Pinkerton R.; Sommelet D.; Brunat-Mentigny M.; Farsi F.; Martel I.; Philip T.; Ranchere-Vince D.; Thiesse P.
Prognostic value of blasts on day 15 in bone marrow and of molecular evaluation of remission in children with acute lymphoblastic leukemia pp. 111-111(1) Authors: Schneider M.; Fasching K.; Stolz F.; Mann G.; Fischer S.; Potschger U.; Gadner H.; Panzer-Grumayer E.R.
Monitoring and functional characterization of rare tumor cells in the haematopoietic system pp. 111-111(1) Authors: Mehes G.; Hattinger C.M.; Lorch T.; Luegmayr A.; Gadner H.; Ambros P.F.
Cutaneoes and subcutaneous Ewing's sarcoma - A relatively indolent disease pp. 111-112(2) Authors: Chow E.; Merchant T.E.; Pappo A.; Jenkins J.; Kun L.E.
Recommended age for total thyroidectomy in children with MEN-2a syndrome pp. 112-112(1) Authors: Kahraman T.; Plukker J.T.M.; Rouwe C.; Tiebosch A.T.M.G.; Hofstra R.; Vermey A.
Second malignant neoplasms (SMNs) in retinoblastoma (RB) pp. 112-112(1) Authors: Chuba P.J.; Hamre M.; Blackburn R.; Roarty J.D.; Taub J.W.; Ravindranath Y.; Fontanesi J.
Early prophylactic treatment with high-dose recombinant human erythropoetin (rHuEPO) in children with solid tumors pp. 112-112(1) Authors: Zoubek A.; Kronberger M.; Fischmeister G.; Potschger U.; Gadner H.
Results of first multicentric studies of therapy children and adolescents with acute lymphoblastic leukemia in Ukraine pp. 112-112(1) Authors: Donska S.; Polischuk R.; Trojanovska O.; Usatchenko V.; Belousova L.; Mischenko I.; Schanina V.; Ivanova I.; Rudko L.; Schevtchenko S.
Incidence of TEL/AML1 fusion genes in children with ALL: risk assessment by BFM and MRD criteria pp. 113-113(1) Authors: Fasching K.; Stolz F.; Knig M.; Fischer S.; Mann G.; Haas O.A.; Gadner H.; Panzer-Grmayer E.R.
Ex vivo purging using MC540 photoirradiation therapy enhanced by amifostine (WR 2721) pp. 113-113(1) Authors: Danilatou V.; Lydaki E.; Dimitriou H.; Bolonaki I.; Kalmanti M.
Radiotherapy for unresectable or marginally resectable osteosarcoma pp. 113-113(1) Authors: Chow E.; Kun L.E.; Merchant T.E.; Kaste S.C.; Pratt C.B.; Shah A.B.
Ewing's sarcoma: a review of treatment outcomes and morbidity in patients aged 16 and less treated in British Columbia between 1980 and 1992 pp. 113-113(1) Authors: Goddard K.; Wu J.; Fryer C.; Rogers P.; Brown K.
Astrocytomas of the cerebellum in children pp. 113-114(2) Authors: Kurtulmaz S.; Serin M.; Akmak A.
Mutations of RB-1 gene in children with leukemia and neuroblastoma pp. 114-114(1) Authors: Markakis E.A.; Tsopanomichalou M.; Dimitriou H.; Spandidos D.A.; Stiakaki E.; Kalmanti M.
Ochrobactrum anthropi bacteremia in children with central venous catheters pp. 114-114(1) Authors: Stiakaki E.; Bolonaki I.; Maraki S.; Samonis G.; Kambourakis A.; Tselentis I.; Kalmanti M.
Changes of thyroid gland after combined treatment for Hodgkin's disease in children pp. 114-114(1) Authors: Parkhomenko R.A.; Shcherbenko O.I.; Snigireva R.Y.; Zelinskaya N.I.; Ardatova G.V.; Nechaeva V.N.
Metastatic brain involvement in children with Ewing's sarcoma pp. 114-115(2) Authors: Abramyuk A.; Shparyk Y.
About distribution of primary children's brain tumors in Kazakstan pp. 115-115(1) Author: Zhylkaidarova A.
Retinoblastoma in Kazakstan between 1956-1990 pp. 115-115(1) Authors: Teleuova T.; Mustaphina G.; Volkova M.
Arthroplasty of the knee after resection of a sarcoma in children pp. 115-115(1) Authors: Vedzizhev G.M.; Vedzizhev B.G.
3 cases of viral encephalitis in pediatric oncohematologic department in patients at the end of chemotherapy treatment pp. 115-115(1) Authors: Bazaluk J.; Ryzhak O.; Derbenjova N.; Galtchinska O.; Donska S.
Acute lymphoblastic leukemia: therapy results in one Pediatric Oncohaematologic Center in Ukraine pp. 115-115(1) Authors: Gattchinska O.; Derbenjova N.; Ryzhak O.; Donska S.
Cefepim and ceftazidime in combination with amikacin in febrile neutropenia of childhood: which regimen is more effective? pp. 115-116(2) Authors: Berrak S.G.; Canpolat C.; Berik P.
Evaluation of neo-adjuvant chemotherapy for efficacy of retinoblastoma treatment pp. 116-116(1) Authors: Kobikov S.; Teleuova T.; Zhylkaidarova A.; Volkova M.; Nurgaliev Z.
Progression markers in serum of patients with multiple myeloma pp. 116-116(1) Authors: Sakalova A.; Herbacek I.; Desser L.; Holomanova D.; Mohr T.
CA 15-3 and CA 27-29 serum markers in monitoring breast cancer patients pp. 116-116(1) Authors: Lauro S.; Lanzetta G.; Trasatti L.; Bordin F.; Bria E.; Reale M.G.; Frati L.
Effects of navelbine (NVB) on the electrophoretic profile of hyaluronidase (HAase) on Lewis lung carcinoma (LLC) pp. 116-116(1) Authors: Voyiatzi S.; Sahpazidou D.; Stravoravdi P.; Papageorgiou A.; Chrysogelou E.; Natsis K.; Toliou T.
Initial levels of the plasma 2 microglobulin in patients with different histological types of non-Hodgkin lymphoma pp. 117-117(1) Authors: Filipovic-Ljeskovic I.; Jelic S.; Tomasevic Z.; Milanovic N.
Prognostic subgroups in patients with brain metastases: an analysis of a database containing 1292 patients pp. 117-117(1) Authors: Lagerwaard F.J.; Levendag P.C.; Schmitz P.I.M.
Expression of tumor suppressor gene p27 in high grade astrocytomas correlates with survival pp. 117-117(1) Authors: Kirla R.; Salminen E.; Haapasalo H.; Talve L.; Kalimo H.
Somatostatin receptor scintigraphy in endocranial tumours and comparative dual isotope study. Tissue characterisation? pp. 117-117(1) Authors: Giannakenas C.; Kalofonos H.P.; Apostolopoulos D.; Petsas T.; Kalogeropoulou C.P.; Iliadis H.; Vassilakos P.J.
Phase I clinical trial with BNCT for patients with glioblastoma (EORTC Protocol 11961) pp. 118-118(1) Authors: Sauerwein W.; Hideghety K.; Moss R.; Goetz C.; Pacquis P.; Rassow J.; Grochulla F.; Haselsberger K.; Wolbers J.; Turowski B.; Fankhauser H.; Stecher-Rasmussen F.; de Vries M.; Gabel D.
Enhanced expression of drug-resistance protein LRP in astrocytic brain tumor cells pp. 118-118(1) Authors: Spiegl-Kreinecker S.; Buchroithner J.; Fischer J.; Micksche M.; Berger W.
Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy pp. 118-118(1) Authors: Grabenbauer G.G.; Roedel C.M.; Paulus W.; Fahlbusch R.; Sauer R.
A brain cancer clinical assessment tool (BC CAT) for monitoring disease status in high-grade gliomas pp. 118-118(1) Authors: Osoba D.; Zee B.; Brada M.; Yung W.K.A.; Weng C.S.W.; MacDonald D.
Comparison of radiotherapy dose distribution and FDG-PET after irradiation in patients with malignant glioma pp. 118-119(2) Authors: Paulsen F.; Muller-Berg M.; Becker G.; Reimold M.; Hipp P.; Hehr T.; Buchgeister M.; Muller-Schauenburg W.; Bares R.; Bamberg M.
Establishment of a nitrosourea-resistant in vivo brain-tumor model: for evaluation of different appraoches to conquer the resistance pp. 119-119(1) Authors: Manome Y.; Watanabe M.; Kunieda T.; Ohno T.
Hypermethylation of the hMLH1 promoter region in high-grade gliomas pp. 119-119(1) Authors: Andion E.; Garcia-Foncillas J.; Salgado E.; Jimenez E.; Huarriz M.; Guzman M.; Okroujnov I.; Vanaclocha V.; Villares G.; Brugarolas A.
Linear accelerator based stereotactic radiosurgery (SRS) as an initial treatment for brain metastases: we can control the tumors 2 cm or less with SRS alone pp. 119-119(1) Authors: Hayashi N.; Uchida T.; Okimoto T.; Minami K.; Hayashida M.; Morikawa M.; Ochi M.; Hayashi K.; Shibata S.; Honda S.
Increased expression of heterodisperse Alu-containing transcripts in glioblastoma multiforme pp. 119-119(1) Authors: Kavsan V.; Dmitrenko V.; Shostak K.; Garifulin O.; Homenko O.; Zozulya Y.
Intraoperative radiotherapy (IORT) for high grade glioma of the brain - Treatment planning, dose verification, and results pp. 120-120(1) Authors: Schueller P.; Ruebe C.; Palkovic S.; Prott F.-J.; Wagner W.; Willich N.
High-dose chemotherapy (HDCT) with G-CSF support before radiotherapy (RT) in malignant gliomas (MG): phase II trial pp. 120-120(1) Authors: Vinolas N.; Gil M.; Verger E.; Villa S.; Pujol T.; Caral L.; Garcia M.; Graus F.; Estape J.
Treatment of glioblastoma multiforme (GBM) with teniposide (VM26) and Iomustine (CCNU) followed by radiotherapy pp. 120-120(1) Authors: Mane J.M.; Barcelo J.R.; Rubio I.; Fernandez R.; Fuente N.; Abon G.; Munoz A.; Lopez-Vivanco G.
Radiotherapy in primary spinal cord astrocytoma pp. 120-120(1) Authors: Ozyigit G.; Zorlu F.; Gurkaynak M.; Cengiz M.; Atahan I.L.
Stereotactic radiotherapy for solitary brain metastases as alternative to surgery pp. 120-121(2) Authors: Kaiser A.; Bohmer D.; Fitzek M.; Koerner M.; Matnjani G.; Rosche L.; Stotzer U.; Stuschke M.; Budach V.; Wurm R.E.
Biological evaluation on short course conformal radiotherapy of malignant gliomas pp. 121-121(1) Authors: Mangel L.C.; Kiss T.; Horvath A.; Skriba Z.; Somogyi A.; Nemeth G.
Preliminary results of a phase II study: irinotecan (CPT 11) in chemotherapy naive patients with glioblastoma pp. 121-121(1) Authors: Fabbro M.; Frenay M.; Raymond E.; Rodier J.M.; Boige V.; Jourdan R.; Risse M.L.; Armand J.P.
Combined therapy of PNET/medulloblastoma in children and young adults - Single institution expirience pp. 121-121(1) Authors: Golubicic I.; Nikitovic M.; Bokun J.; Radosevic-Jelic L.
Continuous hyperfractionated accelerated radiation therapy (chart) with fotemustine for malignant gliomas pp. 121-121(1) Authors: Yaman F.; Altun M.; Altin S.; Tenekeci A.; Bavbek E.; Onat H.
Effect of tiazofurin on cell cycle and apoptosis induction on C6 rat glioma cells pp. 122-122(1) Authors: Vracar M.; Piperski V.; Jokanovic M.; Jovic V.; Rakic L.
A 30-year trek through the arcanes of clinical research pp. 123-123(1) Author: Horiot J.-C.
The genetic profile of marginal zone B-cell lymphoma pp. 123-124(2) Authors: Dierlamm J.; Wlodarska L.; Baens M.; Stefanova M.; Hinz K.; Stul M.; Michaux L.; Verhoef G.; Thomas J.; Hossfeld D.K.; Hagemeijer A.; De Wolf-Peeters C.; Marynen P.; Van den Berghe H.
The causes of cancer pp. 125-125(1) Author: Peto R.
Early breast cancer - the randomised evidence pp. 126-126(1) Authors: Peto R.; Clarke M.; Collins R.; Davies C.; Godwin J.; Gray R.
Improving outlook for ovarian cancer - fact or fiction? pp. 126-126(1) Author: Kaye S.B.
Adjuvant and palliative therapy for colorectal cancer pp. 126-126(1) Author: Glimelius B.
Palliative treatments for metastatic cancer, and use of quality of life endpoints to assess them pp. 126-127(2) Author: Tannock I.F.
Conflict of interest pp. 127-127(1) Author: Holmberg L.
Collaboration between large intergroups and the pharmaceutical industry pp. 127-127(1) Author: Piccart M.J.
The coordinating role of the EORTC pp. 127-127(1) Author: Francoise M.
The view from the pharmaceutical industry pp. 127-127(1) Author: Blackledge G.R.P.
Antigens recognized by T lymphocytes on kidney cancer pp. 128-128(1) Authors: Van den Eynde B.J.; Probst-Kepper M.; Boon T.
Dendritic and tumour cell -derived exosomes as novel cancer vaccines pp. 128-128(1) Authors: Zitvogel L.; Lozier A.; Wolfers J.; Regnault A.; Masurier C.; Fernandez N.; Raposo G.; Amigorena S.
T-cell immunity against tumors, a delicate balancing act involving dendritic cells pp. 128-128(1) Author: Melief C.
Vaccination with gene-modified tumor cells pp. 128-128(1) Author: Parmiani G.
Important issues in palliative oncology pp. 128-129(2) Author: Maher E.J.
Pain control for bone metastases pp. 129-129(1) Authors: Leer J.W.H.; Steenland E.; van Houwelingen H.
Radiation treatment for bone metastases from prostrate cancer pp. 129-129(1) Author: Russell M.
Brain metastases - Radiosurgery or whole brain irradiation? pp. 129-129(1) Authors: Wurm R.E.; Schlenger L.; Kaiser A.; Komer M.; Fitzek M.; Roschel L.; Bohmer D.; Matnjani G.; Stuschke M.; Budach V.
Retreatment in head and neck squamous cell carcinoma pp. 129-130(2) Authors: Bourhis J.; DeCrevoisier R.; Eschwege F.
The estrogen receptor as a target for breast cancer prevention pp. 130-130(1) Author: Jordan C.V.
Coactivators and hormone action pp. 130-130(1) Authors: White R.; Mak H.Y.; Heery D.M.; Kalkhoven E.; Valentine J.; Bevan C.; Parker M.G.
Er - New development pp. 130-130(1) Author: Gustafsson J.-.
Genetic dissection of glucocorticoid receptor function in mice pp. 130-130(1) Author: Schutz G.
New antioestrogens for breast cancer pp. 130-130(1) Author: Howell A.
How to respond to complementary medicine: introduction pp. 130-130(1) Author: Smyth J.F.
The complementary medicine: the promotors, the prescriptors and the users in different countries pp. 131-131(1) Author: Schraub S.
The use of complementary medicine in the German speaking countries pp. 131-131(1) Author: Jungi W.F.
Why do people affected by cancer use complementary therapies and how can their efficacy be evaluated? pp. 131-131(1) Author: Wilkinson S.
Oncology nurses' attitudes towards alternative medicine pp. 131-131(1) Author: Salmenpera L.
The interaction of patient selection, surgical expertise and intensive care competence in esophageal cancer pp. 131-132(2) Author: Lerut T.
Quality of surgery and outcome in gastric cancer surgery pp. 132-132(1) Authors: Beger H.G.; Schwarz A.
Liver tumor surgery: quality of surgery and outcome on the basis of a large interdisciplinary treatment unit pp. 132-132(1) Author: Bismuth H.
Surgical oncology - The volume-outcome impact. Breast cancer pp. 132-132(1) Author: Sainsbury R.
Eps8 and E3b1 mediate transduction of signals from Ras to Rac pp. 132-132(1) Authors: Scita G.; Tenca P.; Panunzio M.; Betsholtz C.; Di Fiore P.P.
In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery pp. 133-133(1) Author: Lacal J.C.
The role of the c-erGB-4/HER4 receptor in cancer pp. 133-133(1) Author: Gullick W.
HER2/neu oncoprotein of human adenocarcinomas: an amplifier of signal transduction by stromal growth factor pp. 133-133(1) Author: Yarden Y.
Oncogenic signalling through small GTPases pp. 133-133(1) Author: Marshall C.J.
Speaker against: are we ready to use tamoxifen to prevent breast cancer in daily practice? pp. 134-134(1) Author: Powles T.J.
MDR - Proteins and their clinical relevance pp. 135-135(1) Authors: Pinedo H.M.; Lankelma J.; Jansen G.; Broxterman H.J.
Can we predict the efficacy and side effect of radiotherapy pp. 135-135(1) Author: Overgaard J.
What constitutes quality in breast cancer surgery pp. 135-135(1) Author: Rutgers E.J.T.
Is age a prognostic factor? pp. 135-136(2) Author: Mott M.G.
Computer-aided oncology: from basic research to clinical practice pp. 136-136(1) Author: Sgouros J.
Knock-out mice in cancer research pp. 136-136(1) Authors: Berns A.; Vooijs M.; Marino S.; Jonkers J.; Meuwissen R.; Vink J.; Van der Gulden H.; Krimpenfort P.
Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer pp. 137-137(1) Authors: Ross P.; Cunningham D.; Scarffe H.; Nicolson M.; Seymour M.; Harper P.; Price T.; Hill A.; Anderson H.; Iveson T.; Hickish T.; Lofts F.; Norman A.
Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC) pp. 137-137(1) Authors: Ducreux M.; Douillard J.Y.; Pignon J.P.; Seitz J.F.; Bugat R.; Bosset J.F.; Merrouche Y.; Raoul J.L.; Ychou M.; Rougier P.
Locally advanced pancreatic carcinoma: neoadjuvant radiochemotherapy (RCT) with 5-fu and Mitomycin C pp. 137-137(1) Authors: Brunner T.B.; Grabenbauer G.G.; Kastl S.; Hohenberger W.; Sauer R.
High incidence of K-Ras mutations in the bile fluids of patients with primary sclerosing cholangitis pp. 137-138(2) Authors: Kubicka S.; Meier P.; Flemming P.; Kumhnel F.; Rudolph K.; Manns M.P.
A randomized trial on hepatic arterial CDDP and i.v. 5-FU in unresectable colorectal liver metastases pp. 138-138(1) Authors: Cosimelli M.; Tedesco M.; Mancini R.; Giannarelli D.; Garufi C.; Tipaldi L.; Cortesi E.; Di Tora P.; Capussotti L.
Basal level gene expression of thymidylate synthase (TS) in colorectal cancer and normal colon mucosa - No evidence of relation to disease course pp. 138-138(1) Authors: Larsson P.-A.; Odin E.; Wettergren Y.; Larsson L.; Carlsson G.; Gustavsson B.
Value of peptide receptor imaging using indium-111-octreotide (OCT) and iodine-123 vasoactive intestinal peptide (VIP) in patients with carcinoid tumours: Vienna University experience 1993-1998 pp. 138-138(1) Authors: Raderer M.; Kurtaran A.; Niederle B.; Vorbeck F.; Vierhapper H.; Scheithauer W.; Angelberger P.; Pidlich J.; Virgolini I.
Health-related quality of life in five-year survivors of endocrine gastrointestinal tumours pp. 138-139(2) Authors: Larsson G.; Sjoden P.O.; Oberg K.; von Essen L.
Advanced esophageal cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil and cisplatin (HLFP regimen) pp. 139-139(1) Authors: Taieb J.; Artru P.; Louvet C.; Mabro M.; Carola E.; Lucchi E.; Krulik M.; de Gramont A.
Tobacco, alcohol and the risk of stomach cancer in Canada pp. 139-139(1) Authors: Hu J.; Mao Y.; Ugnat A.-M.
5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC) pp. 139-139(1) Authors: Roth A.D.; Maibach R.; Fazio N.; Pagani O.; Morant R.; Stupp R.; De Braud F.; Sessa C.; Borner M.M.; Herrmann R.; Goldhirsch A.
Eight-hour infusion versus bolus injection of doxorubicin in EAP regimen in patients with advanced gastric cancer (AGC): a prospective randomised trial pp. 139-139(1) Authors: Popov I.; Jelic S.; Radosavljevic D.; Nikolic-Tomasevic Z.
Randomized trial of preoperative (PRT) and intraoperative (IORT) radiotherapy versus surgery alone in resectable gastric cancer pp. 139-140(2) Authors: Skoropad V.; Berdov B.
Clinical study on intraperitoneal hyperthermic perfusion chemotherapy for patients with gastric cancer pp. 140-140(1) Authors: Cao X.F.; Wu W.M.; Qiu H.Y.; Wu B.C.; Cai M.H.; Za W.Z.
Evaluation for multiple cancer in cases of endoscopic mucosal resection for early gastric carcinoma pp. 140-140(1) Authors: Suzuki T.; Nakamura T.; Matsu-ura A.; Yamao K.; Ohashi K.
Expression of thymidylate synthase and its prognostic value in gastric carcinoma with adjuvant 5-fluorouracil containing chemotherapy pp. 140-140(1) Authors: Lim H.Y.; Choi J.H.; Kim H.S.; Nam D.K.; Kim H.C.; Joo H.J.
Effects of high dose-rate intraluminal brachytherapy (HDR-ILBRT) for the patients with esophageal squamous cell carcinoma (SCC) pp. 140-140(1) Authors: Iwasa M.; Iwasa Y.; Ohmori Y.; Kume M.; Ogoshi S.; Ogawa Y.; Yoshida S.
Effect of T and N stages on outcome of chemoradiation for carcinoma of anus pp. 140-141(2) Authors: Ngan S.; Smith J.; Chao M.; Lim-Joon D.
A phase II study of hypofractionated radiotherapy in combination with Gemcitabin in the palliative treatment of advanced pancreatic carcinoma pp. 141-141(1) Authors: Antonisse I.E.; van Groeningen C.J.; Langendijk J.A.; Slotman B.J.
Phase I/II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer pp. 141-141(1) Authors: Yamao T.; Maruyama M.; Shirao K.; Matsumura Y.; Yamada Y.; Muro K.; Sugano K.; Shimada Y.
Stage-adapted radio-chemotherapy in anal canal carcinoma pp. 141-141(1) Authors: Landmann C.; Amsler B.
Hepatocellular carcinoma: adjuvant chemotherapy postliver transplant pp. 141-142(2) Authors: Villanueva M.J.; Navarro F.; Sanchez A.; Provencio M.; Bonilla F.; Cuervas-Mons V.; Espana P.
Localised squamous - cell cancer of the oesophagus: retrospective analyzis of three results pp. 142-142(1) Authors: Delcambre C.; Jacob J.H.; Segol P.; Ollivier J.M.; Gignoux M.; Pottier D.; Vie B.; Roussel A.
Radio-chemotherapy and high dose rate (HDR) brachytherapy in the treatment of esophageal cancer pp. 142-142(1) Authors: von Briel C.; Borner M.; Greiner R.H.
The royal marsden experience with chemo-radiation using protracted infusional (PVI) 5-fu and cisplatin with conformal radiotherapy (CR-RT) in locally advanced oesophageal cancer pp. 142-142(1) Authors: Tait D.; Walters J.; Norman A.; Ross P.; Cunningham D.
First line treatment with docetaxel (D) and gemcitabine (G) in patients with inoperable pancreatic cancer: a multicenter phase II study pp. 142-143(2) Authors: Androulakis N.; Stathopoulos G.; Tsavaris N.; Aravandinos G.; Samantas E.; Papakostas P.; Kouroussis C.; Fountzilas G.; Kakolyris S.; Mavroudis D.
Direct endoscopic injection of cisplatin/adrenaline gel for palliation of dysphagia in patients with advanced esophageal cancer pp. 143-143(1) Authors: Harbord M.; Viens P.; Eysselein V.; Barr H.; Bown S.G.
Radiochemotherapy in anal canal carcinoma (ACC). A randomized clinical trial comparing FluoroUracil-Cisplatinum (5FU-CDDP) and CDDP alone pp. 143-143(1) Authors: Gerard J.P.; Romestaing P.; Mornex F.; Ardiet J.M.
Complete peritonectomy associated with intra peritoneal hyperthermic perfusion in the treatment of Pseudomyxoma Peritonei: experience at the National Cancer Institute of Milan pp. 143-143(1) Authors: Deraco M.; Santoro N.; Inglese M.G.; Guadagni S.; Maucione A.; Azzarelli A.; Mazzaferro V.; Zanna M.; Vaglini M.
Concurrent high dose radiotherapy and cisplatinum-based chemotherapy +/- immunotherapy versus radiotherapy alone in esophageal carcinoma. Molecular biology in assesment of response to chemoradiotherapy pp. 143-144(2) Authors: Ibrahim S.M.; Ali A.K.; Faraag A.A.; Hamed S.E.; Abdel Hafeez Z.M.
Prognostic value of tumor suppressor gene (P53) and multiple drug resistance transport protein (P170) in hepatocellular carcinoma (HCC) pp. 144-144(1) Authors: Saber M.; Atef H.; Mansour M.; Youssry A.; Abdel-Ghany M.S.; El-Derini S.
3D-conformal radiotherapy (3D-CRT) for pancreatic cancer: acute toxicity and quality of life in the experience of the European Institute of Oncology pp. 144-144(1) Authors: Gatti G.M.; Castiglioni S.; Ghilezan M.; Ivaldi G.B.; Catalano G.; Leonardi M.C.; Greco C.; Vavassori A.; Marsiglia H.; Orecchia R.
A randomised trial of brachytherapy before (BRYB) and after (BRYA) external beam irradiation (XRT) for carcinomas of the oesophagus and cardia pp. 144-144(1) Authors: Haylock B.J.; Hay J.H.; Flores A.D.; Evans K.D.; Nelems B.; Finley R.J.
Phase II study of docetaxel (D) as salvage chemotherapy in patients with advanced gastric cancer pp. 145-145(1) Authors: Vanhoefer U.; Harstrick A.; Wilke H.; Achterrath W.; Preusser P.; Stahl M.; Fink U.; Seeber S.
Transhiatal oesophagectomy in the treatment of carcinoma of the lower oesophagus and cardia of the stomach - influence of preoperative risk factors pp. 145-145(1) Authors: Loukanov T.; Dimitrov V.; Djongov L.
3-Dimensional planned conformal radiation technique (3D-RT) compared to standard 2 isocentric fields AP-PA radiation technique (APPA-RT) in anal cancer pp. 145-145(1) Authors: Gerber E.; Cerveny M.; Krausz H.; Baur M.; Karner J.; Sellner F.; Wunderlich M.; Tuchmann A.; Hold M.; Schratter-Sehn A.
Whole body hyperthermia (WHB, 41.8oC) in combination with chemotherapy in gastrointestinal (GI) cancer pp. 145-145(1) Authors: Panse J.; Nierhaus A.; Meissner-Kuck C.; Hegewisch-Becker S.; Hossfeld D.K.
The role of different preoperative treatment modality in esophageal carcinoma management pp. 145-146(2) Authors: Ganul V.; Bondarouk O.; Kirkilevsky S.; Pidlubna T.; Zajtcev S.
Concurrent chemoradiotherapy using low-dose continuous infusion of 5-fluorouracil for stage 2-3 esophageal cancer: a 3-year follow-up report pp. 146-146(1) Authors: Sakai K.; Sugita T.; Tsuchida E.; Matsumoto Y.; Sasamoto R.
Intra-arterial chemotherapy (iaCT) combined with radiation (RT) for advanced pancreatic cancer pp. 146-146(1) Authors: Osinsky D.; Yugrinov O.; Chorny V.; Rozumej D.
Combination therapy with Oxaliplatin + Gemcitabine in advanced pancreatic cancer pp. 146-146(1) Authors: Klapdor R.; Martini-Svendsen J.; Seutter R.; Fenner C.
Local effect of cisplatin/epinephrine injectable gel on intrahepatic lesions of hepatocellular carcinoma (HCC) pp. 146-146(1) Authors: Yu S.C.H.; Leung T.W.T.; Lau W.Y.; Chan Y.L.; Tang A.M.Y.; Metreweli C.; Johnson P.J.
Phase II trial of high-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma pp. 147-147(1) Authors: Scheithauer W.; Kornek G.; Ulrich-Pur H.; Raderer M.; Fiebiger W.; Zickero G.; Pidlich J.; Greul R.; Schneeweiss B.; Depisch D.
Preoperative chemotherapy with weekly cisplatin plus continous infusion of fluorouracil and hyperfractionated radiation for esophageal cancer pp. 147-147(1) Authors: Font A.; Guillot M.; Fernandez-Llamazares J.; Arellano A.; Boix J.; Casas D.; Abad A.; Rosell R.
Proliferative index and DNA content in precancerous conditions and adenomatous polyps of stomach pp. 147-147(1) Authors: Santos L.; Carneiro F.
Clinical pathway for the management of gastric cancer with peritoneal seeding pp. 147-147(1) Authors: Sugarbaker P.H.; Yonemura Y.
Preoperative short-term radiotherapy of resectable gastric cancer: complete 20-years follow up of a randomized trial pp. 147-148(2) Authors: Skoropad V.; Berdov B.
The influence of trypsin, chymotrypsin and papain on the growth of human pancreatic adenocarcinoma transplanted to nu/nu mice pp. 148-148(1) Authors: Wald M.; Pouckova P.; Hlouskova D.; Altnerova M.; Olejar T.
Gemcitabine (G) in combination radiationtherapy (RT) in stage III-IV pancreatic cancer: first results of a current phase I study pp. 148-148(1) Authors: Maurer U.; Stegmeier P.; Bolte R.; Jungius K.P.; Mueller D.; Georgi M.
Gastric carcinoma: a phase II study of capecitabine with new dosing regimen in patients with advanced/metastatic gastric carcinoma pp. 148-148(1) Authors: Koizumi W.; Ujiie S.; Taguchi T.
Phase II study of gemcitabine (GEM) combined with radiation therapy (RT) in localized, unresectable pancreatic cancer pp. 148-149(2) Authors: Epelbaum R.; Rosenblatt E.; Nasrallah S.; Menashe N.; Yardeni T.; Faraggi D.; Kuten A.
Significant improvement of response rate and survival with cisplatin, epirubicin, 5-fluorouracil and gemcitabine (PEF-G regimen) in metastatic pancreatic cancer pp. 149-149(1) Authors: Reni M.; Ferreri A.J.M.; Panucci M.G.; Cordio S.; Scaglietti U.; Ceresoli G.L.; Bordogna G.; Garassino M.; Villa E.
Periampullary carcinoma: impact of adjuvant chemoradiotherapy on outcome pp. 149-149(1) Authors: Rastogi N.; Prasad S.N.; Sikora S.S.; Ayyagari S.; Datta N.R.
Long term results with the surgical treatment of resectable gastric cancer pp. 149-149(1) Authors: Guimaraes dos Santos J.B.; Silva H.; Cunha D.; Santos L.; Guerra J.P.; Guimaraes dos Santos J.
Submucosal tumors of the esophagus: diagnostic role of endoscopic ultrasonography pp. 149-149(1) Authors: Buda C.A.; Maisano C.; Bene A.; Rizzotti P.; Giudice A.; Lupo G.; La Torre F.
Cisplatin /5-FU (DDP/FU) as 2nd-line chemotherapy after CPT-11 (Irinotecan) failure for patients with metastatic gastric adenocarcinoma pp. 149-150(2) Authors: Thuss-Patience P.C.; Kretzschmar A.; Tilgner J.; Charles A.; Dorken B.; Reichardt P.
Continuous infusion 5-Fluorouracil with or without cisplatin for the treatment of advanced gastric cancer. Results of two consecutive phase II trials of the Spanish Group for Gastrointestinal Tumor Therapy (TTD) pp. 150-150(1) Authors: Cervantes A.; Navarro M.; Carrato A.; Sastre J.; Anton A.; Vicent J.; Tabernero J.; Aparicio J.; Escudero P.; Diaz-Rubio E.
MRI in the long term follow up of patients treated with chemo-radiation (CRT) for anal cancer pp. 150-150(1) Authors: Tait D.; Dzik-Djuraz A.; Husband J.; Glees J.; Essapen S.; Abson C.; Brooker S.
Quality of life as outcome parameter in gastrointestinal (GI) surgery EORTC-QLQ-C-30 and tumor specific modules pp. 150-150(1) Authors: Schmidt C.; Reibe F.; Kuchler T.; Kremer B.
Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil and calcium folinate in stag
Shopping cart
